

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Health promotion at the workplace setting: a protocol for a systematic review of effectiveness and sustainability of current practice in Sub-Saharan African countries

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027050
Article Type:	Protocol
Date Submitted by the Author:	04-Oct-2018
Complete List of Authors:	Wanjau, Mary; Griffith University School of Medicine, ; School of Nursing, University of Nairobi, Kenya, Zapata-Diomed, Belen; Griffith University School of Medicine Veerman, Lennert; Griffith University, School of Medicine; The University of Queensland, School of Public Health
Keywords:	PUBLIC HEALTH, QUALITATIVE RESEARCH, OCCUPATIONAL & INDUSTRIAL MEDICINE, Health Promotion

SCHOLARONE™  
Manuscripts

**Title**

Health promotion at the workplace setting: a protocol for a systematic review of effectiveness and sustainability of current practice in Sub-Saharan African countries

**Corresponding Author**

Mary Njeri Wanjau

School of Medicine, Gold Coast Campus, Griffith University

170 Kessels Road, Nathan. Brisbane, Queensland 4111, Australia.

[mary.wanjau@griffithuni.edu.au](mailto:mary.wanjau@griffithuni.edu.au)

+61 (0) 484274134

**Co- authors**

Dr. Belen Zapata- Diomedi

School of Medicine, Griffith University, QLD 4222, Australia.

Gold Coast campus, Parklands Drive, Southport, QLD, 4222

[b.zapatadiomedi@griffith.edu.au](mailto:b.zapatadiomedi@griffith.edu.au)

Professor. Lennert Veerman

School of Medicine, Griffith University, QLD 4222, Australia.

Gold Coast campus, Parklands Drive, Southport, QLD, 4222

[l.veerman@griffith.edu.au](mailto:l.veerman@griffith.edu.au)

**Word Count**

2280

# Health promotion at the workplace setting: a protocol for a systematic review of effectiveness and sustainability of current practice in Sub-Saharan African countries

## ABSTRACT

### Introduction

Countries in sub-Saharan Africa (SSA) are experiencing a growing disease burden due to non-communicable diseases (NCDs). Changing behavioural practices such as, diets high in saturated fat, salt and sugar, sedentary lifestyles, have been linked to this chronic disease. Health promotion at the workplace setting is considered effective in the fight against this burden of disease, and has been reported to yield numerous benefits. However, there is need to generate evidence on effective and sustainable workplace health promotion (WHP) specific to SSA. We aim to synthesize the current literature on WHP in countries in SSA focusing on effectiveness and sustainability of the interventions.

### Methods and analysis

We will conduct a systematic review of published studies in SSA up to 30<sup>th</sup> September 2018. We will search the following databases: EMBASE, MEDLINE, PubMed, Web of Science, Scopus, ProQuest, and CINAHL. Two reviewers will independently screen potential articles for inclusion and disagreements will be resolved by consensus. We will appraise the quality and risk of bias of included studies using tools from Cochrane handbook for systematic reviews of interventions. We will carry out a descriptive synthesis of the results obtained to establish how effective and sustainable the interventions were. We will conduct a thematic analysis to identify the main focus areas of current interventions. This systematic review protocol has been prepared according to the Preferred Reporting Items for Systematic reviews and Meta- analyses for Protocols (PRISMA-P) 2015 statement.

### Ethics and dissemination

This study does not require ethics approval. We will disseminate the results of this review through peer-reviewed publications and conference presentations.

### Trial registration

This review protocol was submitted for registration in the PROSPERO International Prospective Register of systematic reviews on the 3<sup>rd</sup> of October, 2018.

### Keywords

Health promotion, workplace, systematic review, effectiveness, sustainability, Africa.

### Strengths and limitations of this study

- This is a comprehensive review that examines multiple workplaces, across various industries in the sub-Saharan African region.

- The review search dates cover a long period of time providing for a comprehensive search for relevant articles.
- The methods of this review have been outlined in a protocol guarding against arbitrary decision making in the review process.
- Our search strategy is restricted by language where studies included will be limited to those that are published in the English language.
- The inclusion of diverse study designs, reporting on different intervention types makes this a heterogeneous study that may limit the extent to which the results are analysed.

## INTRODUCTION

### Rationale

Globally, 41 million deaths (71% of all deaths) were due to non-communicable diseases (NCDs) [1]. The majority of these deaths were caused by: cardiovascular disease (44%); cancer (22%); chronic respiratory disease (9%); and diabetes (4%) [1]. In 2014, World Health Organisation (WHO) estimated a 17% increase of deaths from NCDs globally and a 27% increase for the African region, equivalent to 28 million additional deaths by 2030 [2]. WHO [3] estimated that by 2020, NCDs will be as prevalent as communicable diseases in sub-Saharan Africa (SSA). Already, NCDs are the main cause of adult deaths in Mauritius, Namibia and Seychelles [2].

The leading risks factors associated with the global increase in mortality are high blood pressure (responsible for 13% of death globally), tobacco use (9%), high blood glucose (6%), physical inactivity (6%), and overweight and obesity (5%) [4]. In SSA, changing behavioural practices has been linked to the chronic disease burden and the changes attributed to structural factors such as urbanisation, industrialisation [5], and food market globalisation [6]. The reversal or mitigation of this trend in SSA calls for the application of effective principles and practices of health promotion [7] and the mainstreaming of health promotion [8]. The current WHO health promotion strategy for the African region petitions governments to go beyond the focus on health behaviour which puts the burden of health improvement mainly on the individual, and address environmental, legislative, and policy changes [9].

Health promotion is described as “the process that enables people to increase control over (health determinants), and to improve their health” [10]. The 1997 Jakarta declaration affirmed that health promotion strategies were indeed effective in addressing health risk

1  
2  
3 factors [11], particularly lifestyle related risk factors which can be modified to prevent  
4 disease [3].

5  
6 Nyamwaya [12] points out that the use of health promotion as a means of increasing societal  
7 responsibility for health now exists in all African countries. Laws and policies that facilitate  
8 adoption of healthy lifestyles and disease prevention such as tobacco legislation, have been  
9 put in place [12]. A focus on settings for health promotion has enabled the creation of  
10 supportive environments through the development of relevant, practical health promotion  
11 interventions that address a full range of health determinants at each setting [13]. The  
12 introduction of the settings approach for health promotion followed the 1986 Ottawa  
13 Charter's declaration that "health is created and lived by people within the settings of their  
14 everyday life, where they learn, work, play and love"[10]. The settings approach has  
15 translated to the utilisation of "the health potentials inherent in the social and institutional  
16 settings of everyday life" [14]. Settings identified in the Ottawa charter included: prisons,  
17 schools, universities, market places, hospitals, islands, districts, cities, regions and  
18 workplaces [10].

19  
20 The workplace as a health promotion setting presents an opportunity to reach a large number  
21 of people within the adult population [15]. The working population is one that would not  
22 normally be engaged in organised health improvement initiatives [16]. WHO has estimated  
23 that workers are estimated to represent half of the world's population [17] and a majority of  
24 them spend a substantial portion of their waking hours at work [18]. Workplace health  
25 promotion (WHP) interventions are defined as employer initiatives directed at protecting the  
26 health of employees and thereby improving their productivity [19]. Beyond individual  
27 factors, a health promoting workplace adopts an ongoing process that addresses the multiple  
28 determinants of workers' health such as: organizational, environmental, and societal and  
29 community factors [16, 20-26].

30  
31 WHP can help contain the current epidemic of lifestyle-related diseases [27]. When properly  
32 designed and implemented, WHP initiatives have been associated with multiple benefits such  
33 as: workers' positive lifestyle changes [16, 27], positive return on investment for the  
34 organisation [28-30], improved productivity and employee performance [31, 32], reduced  
35 medical costs [28, 31], reduced absenteeism costs [28, 33], lowered disease prevalence [34,  
36 35], and increased organizational competitiveness [16]. The initiatives have also been  
37 observed to produce happier and loyal employees [30, 36-39]. Nonetheless, it is notable that  
38 reviews for health promotion interventions have limited their focus to individual  
39 interventions, leaving out interventions that focus on environmental, structural and social  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

determinants of health [38, 40]. With limited research on interventions focusing on multiple health determinants, employers have also shown reluctance to offer sufficiently comprehensive WHP programs because they are not fully persuaded of their benefits, and they also contend that there are few best practices for them to emulate [16, 41]. In addition, most of the published research in WHP has been reported from developed countries and there is scarcity of WHP reported in the low and middle income countries [31].

In SSA, there is a gap in the provision of evidence-based health promotion interventions at the workplace [42]. There is a need to generate evidence to justify strategic WHP choices and “best buy” interventions [7, 12]. A systematic review that synthesizes multiple published studies on WHP in SSA will help establish evidence for WHP effectiveness and sustainability specific to this region. With evidence on effective and sustainable WHP practice, a scale up of the implementation of effective, feasible interventions within SSA will be made possible. We therefore propose to carry out a systematic review that aims to synthesise published studies on current WHP practice in countries in Sub Saharan Africa focusing on effectiveness and sustainability of the interventions.

### **Objective**

To conduct a comprehensive synthesis of the current WHP practice in countries within the Sub Saharan Africa focusing on effectiveness and sustainability of interventions, all through until 30<sup>th</sup> September 2018.

### **Review Questions**

We aim to address the following questions:

1. How effective are the WHP interventions in countries within Sub Saharan Africa?
2. How sustainable is WHP in countries within Sub Saharan Africa?

### **METHODS**

This review protocol was submitted for registration in the PROSPERO International Prospective Register of systematic reviews on the 3<sup>rd</sup> of October, 2018. The review has been prepared according to the Preferred Reporting Items for Systematic reviews and Meta-Analysis Protocols (PRISMA-P) 2015 statement [43].

In synthesis and description of current WHP practice in Sub Saharan Africa, the review will address the six priority action areas of the Ottawa Charter declaration [10]. Evidence of effectiveness of the WHP interventions will be limited to assessing whether set out

intervention goals were actually achieved as presented in the research papers. In line with the WHO framework for WHP, aspects of sustainability will also be assessed from the synthesized literature. Assessment for sustainability will be guided by; full integration or institutionalisation of a program within an organisation, inclusion of capacity building in the workplace, community involvement/participation in the program and maintenance of health benefits from the program [44, 45].

### Inclusion Criteria

- a) Intervention type: health promotion at the workplace setting. Studies that do not report on WHP as whole will be excluded; for example, studies reporting on a standalone aspect such as safety, hospitals or treatment.
- b) Setting: workplaces within Sub-Saharan Africa.
- c) Publication: peer reviewed primary studies whose full text is publicly available. We will review the reference lists from past reviews and other non-primary studies for suitable studies that would meet the inclusion criteria. Duplicate publications of the same material will be excluded. For studies published in multiple journals, the most recent version will be considered.
- d) Study designs: all study designs will be included since HP interventions are evaluated using a wide variety of approaches and study designs [46-48].
- e) Language: English.

### Data Sources and Search Strategy

We will search the following databases: Excerpta Medica Database (Embase), Medical Literature Analysis and Retrieval System Online (MEDLINE), PubMed, Web of Science, Scopus, ProQuest, Cumulative Index to Nursing and Allied Health Literature (CINAHL).

Table 1 shows the search strategy that we will use and we will adapt it to the different databases.

Table 1 Search strategy

#### Search terms

"Workplace" OR "occupational" OR "worksite" OR "organi\*ational" OR "industrial" OR "work" OR "worker" OR "employee"

AND

"Health\*" OR "health promotion" OR "Wellness" OR "Well-being" "wellbeing" OR



---

“health management” OR “Health protection” OR “  
AND  
“Program\*” OR “framework” OR “model” OR “intervention” OR “initiative”  
AND  
“Angola” OR “Benin” OR “Botswana” OR “Burkina Faso” OR “Burundi” OR “Cabo Verde” OR “Cameroon” OR “Central African Republic” OR “Chad” OR “Comoros” OR “Congo” OR “Democratic Republic of Congo” OR “Côte d’Ivoire” OR “Equatorial Guinea” OR “Eritrea” OR “Ethiopia” OR “Gabon” OR “Gambia” OR “The Gambia” OR “Ghana” OR “Guinea” OR “Guinea-Bissau” OR “Kenya” OR “Lesotho” OR “Liberia” OR “Madagascar” OR “Malawi” OR “Mali” OR “Mauritania” OR “Mauritius” OR “Mozambique” OR “Namibia” OR “Niger” OR “Nigeria” OR “Rwanda” OR “São Tomé and Príncipe” OR “Senegal” OR “Seychelles” OR “Sierra Leone” OR “Somalia” OR “South Africa” OR “South Sudan” OR “Sudan” OR “Swaziland” OR “Tanzania” OR “Togo” OR “Uganda” OR “Zambia” OR “Zimbabwe” OR “Africa” OR “sub-Saharan Africa”  
AND NOT “Occupational Health and Safety”

---

## Study Records

### Data Management

We will import all identified studies to EndNote X8 software where duplicate records will be identified and excluded from record. In our study selection process, we will be guided by the inclusion criteria. We will use Rayyan QCRI [49], an internet based program to assist the screening and selection of studies.

### Screening

Two reviewers (MW and LB) will independently select all studies that meet the inclusion criteria. The reviewers will screen the titles and abstracts of the studies for relevance based on the criteria set. They will then screen the full texts of potential eligible studies for inclusion and relevance. Any disagreements will be resolved by the two reviewers by consensus. The details of the excluded studies will be documented and presented in a flow chart.

### Data Extraction

Using a predetermined data extraction sheet, two reviewers will independently extract data from final full texts of eligible studies and any inconsistencies will be resolved by consensus.

## Data Items

We will extract the following data from our final selection: details of publication (author, author country of affiliation, year of publication, title of article, name of journal study published in), geographical location of intervention, study context (workplace/ industry type, single or multiple organisations studied), subjects of research (role/description of target population, if study is gender specific, employment type of participants, profession), aim of the study, program/intervention priority area focus, sustainability aspects of program, methods, study outcomes, study conclusions, limitations and future research areas proposed.

## Risk of Bias and Quality Appraisal

Two reviewers will independently rate the quality and risk of bias of included studies using tools from Cochrane handbook for systematic reviews of interventions and the results will be presented in a table format. To assess the quality of studies included, the reviewers will use the criteria from Cochrane Handbook for Systematic reviews on international version 5.1.0 [50]. To assess the risk of bias, the reviewers will use the Cochrane tool (table 2) commonly used for Random Controlled Trials adapting it to this review as per the guidelines [51]. We will assign a judgement of 'low', 'high' or 'unclear risk' of bias in the review authors' judgement column. We will report a summary assessment of risk of bias showing the proportion of information that comes from selected studies at low, unclear or high risk of bias for each item in the tool.

Table 2 The Cochrane tool for assessing risk of bias		
Domain	Support for Judgement	Review authors' judgement
<b>Selection bias</b>		
Random sequence generation: selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence.		
Allocation concealment: selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment.		
<b>Performance bias</b>		
Blinding or participants and personnel:		

performance bias due to knowledge of the allocated interventions by participants and personnel during the study.		
Blinding of outcome assessment: detection bias due to knowledge of the allocated interventions by outcome assessors.		
<b>Attrition bias</b>		
Incomplete outcome data: attrition bias due to amount, nature or handling of incomplete outcome data.		
<b>Reporting bias</b>		
Selective reporting: reporting bias due to selective outcome reporting.		
<b>Other bias</b>		
Bias due to problems not covered elsewhere in the table.		

### Data Synthesis

We will use descriptive analysis to present and discuss the studies by geographical regions, regional spread of study authors, number of studies per year, journals that have published these studies, type of workplaces studied, and description of research participants, methods and study outcomes. We will draw out summaries and comparisons from data extracted.

The reviewers will carry out a thematic analysis to present and discuss the Ottawa Charter priority action areas reflected in the synthesized studies with the main themes across different workplace types, time periods and geographical distribution presented and discussed. We will also run a comparison of these aspects across the four country classification by income. In addition to the manual coding and analysis, we will complement the thematic analysis with the use of Leximancer Version 4 software.

### Patient and Public Involvement

We will not involve patients and the public in this review.

### Reporting this review

We will report the systematic review according to the checklist of items to include when reporting a systematic review as per the PRISMA 2009 statement [52]. We will present a flow diagram to show the study selection process, specifying reasons for exclusion at each stage. The study quality appraisal tool will be available as online supplementary material.

### **Potential amendments**

In case of any changes to this protocol, we will outline the details of the changes in the final report. However, no further amendments to this protocol are foreseen.

### **Conclusion**

To heed to the WHO's clarion call to implement and scale-up effective health promotion interventions in Africa [2], there is a need to assess what has been effective and sustainable in the context of the workplace setting. There is need to "...establish what has worked...and what should be done here and now, to improve the health of the people of this Region" [2].

Previous reviews on WHP focused on the effectiveness of specific interventions; for example, on physical activity [53, 54], nutrition promotion [55] and smoking cessation [37]. Through this comprehensive review, we will provide new insights by presenting a holistic outline of current WHP practice in sub-Saharan Africa, with a focus on effectiveness and sustainability.

### **Ethics and dissemination**

Since systematic reviews are based on available published data, this review will therefore not require any formal ethical approval. We will disseminate the results of this systematic review through peer-reviewed publications and conference presentations.

### **Authors' Contributions**

MNW conceived the paper and wrote the first draft. BZD and JLV provided revisions to the manuscript. All authors read and approved the final manuscript. MNW is the guarantor of the review.

### **Data sharing Statement**

All data for this manuscript are included in the submission.

### **Funding Statement**

This research received no specific grant from any funding agency in the public, commercial or not-for profit sectors.

## Competing interests Statement

None declared.

## REFERENCES

1. World Health Organisation, *World Health Statistics*. 2018.
2. WHO, *The African Regional Health Report: The Health of the People*. 2014.
3. WHO, *Chronic diseases and health promotion: Preventing chronic diseases: a vital investment*. 2005.
4. WHO, *Health Promotion: 7th Global Conference on Health Promotion, Nairobi Call to Action*. 2009a.
5. Aikins, et al., *Developing effective chronic disease interventions in Africa: insights from Ghana and Cameroon*. *Globalization and health*, 2010. **6**(1): p. 6.
6. Prentice, A.M., *The emerging epidemic of obesity in developing countries*. *Int J Epidemiol*, 2006. **35**(1): p. 93-9.
7. K.A. Sampson, U., M. Amuyunzu-Nyamongo, and G. Mensah, *Health Promotion and Cardiovascular Disease Prevention in Sub-Saharan Africa*. Vol. 56. 2013. 344-355.
8. WHO, *Global Health Risks*. 2009b.
9. WHO, *Health Promotion: Strategy for the African Region*. 2013.
10. WHO, *The Ottawa Charter for Health promotion: an International Conference on Health Promotion, the move towards a new public health*. 1986: Geneva.
11. WHO, *Health Promotion: Jakarta Declaration on Leading Health Promotion into the 21st Century*. 1997.
12. Nyamwaya, D., *Health promotion in Africa: strategies, players, challenges and prospects*. Health Promotion International, 2003. **18**(2): p. 85-87.
13. Nutbeam, D., *What would the Ottawa Charter look like if it were written today?* Vol. 18. 2008. 435-441.
14. Kickbusch and Ilona, *Tribute to Aaron Antonovsky—'What creates health'*. Health Promotion International, 1996. **11**(1): p. 5-6.
15. Lankford, et al., *Workplace Health: Engaging Business Leaders to Combat Obesity*. *Journal of Law, Medicine & Ethics*, 2013. **41**: p. 40-45.
16. Goetzel Ron Z and O.R. J, *The health and cost benefits of work site health-promotion programs*. *Annu. Rev. Public Health*, 2008. **29**: p. 303-323.
17. WHO, *Workers' health: global plan of action*. 2007.
18. Conrad, P., *Health and fitness at work: A participants' perspective*. *Social Science & Medicine*, 1988. **26**(5): p. 545-550.
19. Harden A, et al., *A systematic review of the effectiveness of health promotion interventions in the workplace*. *Occup Med (Lond)*, 1999. **49**(8): p. 540-8.
20. Chu, C., T. Driscoll, and S. Dwyer, *The health-promoting workplace: an integrative perspective*. *Australian & New Zealand Journal of Public Health*, 1997. **21**(4): p. 377-385.
21. Ziglio, E., *Repositioning health promotion*. *Researching health promotion*, 2000: p. 23.
22. Wenzel, E., *A comment on settings in health promotion*. *Internet Journal of Health Promotion*, 1997.
23. Poland Blake D, Green Lawrence W, and R. Irving, *Settings for health promotion: linking theory and practice*. 1999: Sage Publications.
24. Holman, C.D., et al., *Association of the health-promoting workplace with trade unionism and other industrial factors*. *American Journal of Health Promotion*, 1998. **12**(5): p. 325-334.
25. Tannahill, A., *Health education and health promotion: planning for the 1990s*. *Health Education Journal*, 1990. **49**(4): p. 194-198.

26. Baric, L., *The settings approach—implications for policy and strategy*. Journal of the Institute of Health Education, 1993. **31**(1): p. 17-24.
27. Mattke S, et al., *Workplace Wellness Programs Study: Final Report*. Rand Health Q, 2013. **3**(2): p. 7.
28. Chapman, L.S., *Meta-evaluation of worksite health promotion economic return studies: 2005 update*. Am J Health Promot, 2005. **19**(6): p. 1-11.
29. Burton, W.N., et al., *The association of medical conditions and presenteeism*. J Occup Environ Med, 2004. **46**(6 Suppl): p. S38-45.
30. Aldana, S.G., *Financial impact of health promotion programs: a comprehensive review of the literature*. Am J Health Promot, 2001. **15**(5): p. 296-320.
31. Eng, J.Y., F.M. Moy, and A. Bulgiba, *Impact of a Workplace Health Promotion Program on Employees' Blood Pressure in a Public University*. PLoS ONE, 2016. **11**(2): p. e0148307.
32. Goetzel, R.Z., et al., *Promising practices in employer health and productivity management efforts: findings from a benchmarking study*. J Occup Environ Med, 2007. **49**(2): p. 111-30.
33. Gates, D.M., et al., *Obesity and presenteeism: the impact of body mass index on workplace productivity*. J Occup Environ Med, 2008. **50**(1): p. 39-45.
34. Berry, L.L., A.M. Mirabito, and W.B. Baun, *What's the hard return on employee wellness programs?* Harv Bus Rev, 2010. **88**(12): p. 104-12, 142.
35. Pelletier, K.R., *A review and analysis of the clinical and cost-effectiveness studies of comprehensive health promotion and disease management programs at the worksite: update VIII 2008 to 2010*. J Occup Environ Med, 2011. **53**(11): p. 1310-31.
36. Fitzgerald, C.J. and K.M. Danner, *Evolution in the office: how evolutionary psychology can increase employee health, happiness, and productivity*. Evol Psychol, 2012. **10**(5): p. 770-81.
37. Moher, M., et al., *Workplace interventions for smoking cessation*. Cochrane Database of Systematic Reviews, 2005(2).
38. Wilson, M.G., P.B. Holman, and A. Hammock, *A comprehensive review of the effects of worksite health promotion on health-related outcomes*. Am J Health Promot, 1996. **10**(6): p. 429-35.
39. Pelletier, K.R., *A review and analysis of the clinical and cost-effectiveness studies of comprehensive health promotion and disease management programs at the worksite: update VII 2004-2008*. J Occup Environ Med, 2009. **51**(7): p. 822-37.
40. Jackson, N. and E. Waters, *Criteria for the systematic review of health promotion and public health interventions*. Health Promot Int, 2005. **20**(4): p. 367-74.
41. Linnan, L., et al., *Results of the 2004 National Worksite Health Promotion Survey*. American Journal of Public Health, 2008. **98**(8): p. 1503-1509.
42. Patel, D., et al., *The Healthiest Company Index: a campaign to promote worksite wellness in South Africa*. J Occup Environ Med, 2013. **55**(2): p. 172-8.
43. David Moher, L.S., Mike Clarke, Davina Gherzi, Alessandro Liberati, Mark Petticrew, Paul Shekelle, Lesley A Stewart and PRISMA-P Group *Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement*. 2015.
44. Bossert, T.J., *Can they get along without us? Sustainability of donor-supported health projects in Central America and Africa*. Soc Sci Med, 1990. **30**(9): p. 1015-23.
45. Shediak-Rizkallah, M.C. and L.R. Bone, *Planning for the sustainability of community-based health programs: conceptual frameworks and future directions for research, practice and policy*. Health Educ Res, 1998. **13**(1): p. 87-108.
46. Baum, F., *Researching public health: behind the qualitative-quantitative methodological debate*. Soc Sci Med, 1995. **40**(4): p. 459-68.
47. Donner, A. and N. Klar, *Pitfalls of and controversies in cluster randomization trials*. American Journal of Public Health, 2004. **94**(3): p. 416-422.
48. Glasziou, P., J. Vandenbroucke, and I. Chalmers, *Assessing the quality of research*. Bmj, 2004. **328**(7430): p. 39-41.

- 1  
2  
3 49. Mourad Ouzzani, H.H., Zbys Fedorowicz, and Ahmed Elmagarmid. . *Rayyan — a web and*  
4 *mobile app for systematic reviews*. 2016 [cited 2018 15th September 2018]; 5:210:[DOI:  
5 10.1186/s13643-016-0384-4].  
6 50. Reeves BC, D.J., Higgins JPT, Wells GA, *Including non-randomized studies*. , in *Cochrane*  
7 *Handbook for Systematic Reviews of Interventions*, G.S. Higgins JPT, Editor. 2011, The  
8 Cochrane Collaboration.  
9 51. Higgins, A., Sterne JAC *Assessing risk of bias in included studies*. 2011: Cochrane Handbook  
10 for Systematic Reviews of Interventions  
11 52. Moher, D., et al., *Preferred reporting items for systematic reviews and meta-analyses: the*  
12 *PRISMA statement*. PLoS Med, 2009. **6**(7): p. e1000097.  
13 53. Marshall, A.L., *Challenges and opportunities for promoting physical activity in the workplace*.  
14 *Journal of science and medicine in sport / Sports Medicine Australia*, 2004. **7**(1 Suppl): p. 60-  
15 66.  
16 54. Proper, K.I., et al., *The effectiveness of worksite physical activity programs on physical*  
17 *activity, physical fitness, and health*. *Clinical Journal of Sport Medicine*, 2003. **13**(2): p. 106-  
18 117.  
19 55. Janer, G., M. Sala, and M. Kogevinas, *Health promotion trials at worksites and risk factors for*  
20 *cancer*. *Scandinavian Journal of Work, Environment and Health*, 2002. **28**(3): p. 141-157.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Quality Appraisal tool from *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011).

Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: Including non-randomized studies. In: Higgins JPT, Green S (editors), *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [www.handbook.cochrane.org](http://www.handbook.cochrane.org).

Developing criteria for including non-randomized studies > Table 13.2.a: List of study design features (studies with allocation to interventions at the

**Table 13.2.a: List of study design features (studies with allocation to interventions at the individual level)**

	RCT	Q-RCT	NRCT	CBA	PCS	RCS	HCT	MC	CC	XS	BA	CR/CS
<i>Was there a comparison:</i>												
Between two or more groups of participants receiving different interventions?	Y	Y	Y	Y	Y	Y	Y		Y	Y	N	N
Within the same group of participants over time?	P	P	N	Y	N	N	N		N	N	Y	N
<i>Were participants allocated to groups by:</i>												
Concealed randomization?	Y	N	N	N	N	N	N		N	N	na	na
Quasi-randomization?	N	Y	N	N	N	N	N		N	N	na	na
By other action of researchers?	N	N	Y	P	N	N	N		N	N	na	na
Time differences?	N	N	N	N	N	N	Y		N	N	na	na
Location differences?	N	N	P	P	P	P	P		na	na	na	na
Treatment decisions?	N	N	N	P	P	P	N		N	P	na	na
Participants' preferences?	N	N	N	P	P	P	N		N	P	na	na
On the basis of outcome?	N	N	N	N	N	N	N		Y	P	na	na
Some other process? (specify)												
<i>Which parts of the study were prospective:</i>												
Identification of participants?	Y	Y	Y	P	Y	N	P*		N	N	P	P
Assessment of baseline and allocation to intervention?	Y	Y	Y	P	Y	N	P*		N	N	na	na
Assessment of outcomes?	Y	Y	Y	P	Y	P	P		N	N	P	P



Generation of hypotheses?	Y	Y	Y	Y	Y	Y	Y	Y	P	P	P	na
<i>On what variables was comparability between groups assessed:</i>												
Potential confounders?	P	P	P	P	P	P	P	P	P	P	N	na
Baseline assessment of outcome variables?	P	P	P	Y	P	P	P	P	N	N	N	na

Y=Yes; P=Possibly; P\*=Possible for one group only; N=No; na=not applicable. NB: Note that 'possibly' is used in the table to indicate cells where either 'Y' or 'N' may be the case. It should not be used as a response option when applying the checklist; if uncertain, the response should be 'can't tell' (see [Box 13.4.a](#)).

RCT=Randomized controlled trial; Q-RCT=Quasi-randomized controlled trial; NRCT=Non-randomized controlled trial; CBA=Controlled before-and-after study; PCS=Prospective cohort study; RCS=Retrospective cohort study; HCT=Historically controlled trial; NCC=Nested case-control study; CC=Case-control study; XS=Cross-sectional study; BA=Before-and-after comparison; CR/CS=Case report/Case series

Table 13.2.b: List of study design features (studies with allocation to interventions at the group

**Table 13.2.b: List of study design features (studies with allocation to interventions at the group level)**

	CIRCT	CIQ-RCT	CINRT	CITS	CChBA	ITS	ChBA	EcoXS
<i>Was there a comparison:</i>								
Between two or more groups of clusters receiving different interventions?	Y	Y	Y	Y	Y	N	N	Y
Within the same group of clusters over time?	P	P	N	Y	N	Y	Y	N
<i>Were clusters allocated to groups by:</i>								
Concealed randomization?	Y	N	N	N	N	N	N	N
Quasi-randomization?	N	Y	N	N	N	N	N	N
By other action of researchers?	N	N	Y	P	P	N	N	N
Time differences?	N	N	N	Y	Y	Y	Y	N
Location differences?	N	N	P	P	P	N	N	P
Policy/public health decisions?	Na	na	P	P	P	P	na	na
Cluster preferences?	Na	na	P	P	P	P	na	na
Some other process? (specify)								
<i>Which parts of the study were prospective:</i>								
Identification of participating clusters?	Y	Y	Y	P	P	P	P	N
Assessment of baseline and allocation to intervention?	Y	Y	Y	P	P	P	P	N

Assessment of outcomes?	Y	Y	Y	P	P	P	P	N
Generation of hypotheses?	Y	Y	Y	Y	Y	Y	Y	P
<i>On what variables was comparability between groups assessed:</i>								
Potential confounders?	P	P	P	P	P	P	P	P
Baseline assessment of outcome variables?	P	P	P	Y	Y	Y	Y	N

Note that 'cluster' refers to an entity (e.g. an organization), not necessarily to a group of participants; 'group' refers to one or more clusters; see [Box 13.4.a](#).

Note that 'possibly' is used in the table to indicate cells where *either* 'Y' or 'N' may be the case. It should not be used as a response option when applying the checklist; if uncertain, 'can't tell' should be used (see [Box 13.4.a](#)).

Y=Yes; P=Possibly; P\*=Possible for one group only; N=No; NR=Not required. CIRCT=Cluster randomized controlled trial; CIQ-RCT=Cluster quasi-randomized controlled trial; CINRT=Cluster non-randomized controlled trial; CITS=Controlled interrupted time series (Shadish 2002); CChBA=Controlled cohort before-and-after study (Shadish 2002); ITS=Interrupted time series; ChBA=Cohort before and after study (Shadish 2002); EcoXS=Ecological cross-sectional study.

**Box 13.4.a: User guide for data collection/study assessment using checklist in [Table 13.2.a](#) or [Table 13.2.b](#)**

Note: Users need to be very clear about the way in which the terms 'group' and 'cluster' are used in these tables. [Table 13.2.a](#) only refers to groups, which is used in its conventional sense to mean a number of individual participants. With the exception of allocation on the basis of outcome, 'group' can be interpreted synonymously with 'intervention group'. [Table 13.2.b](#) refers to both clusters and groups. In this table, 'clusters' are typically an organizational entity such as a family health practice, or administrative area, not an individual. As in [Table 13.2.a](#), 'group' is synonymous with 'intervention group' and is used to describe a collection of allocated units, but in [Table 13.2.b](#) these units are clusters rather than individuals. Furthermore, although individuals are nested in clusters, a cluster does not necessarily represent a fixed collection of individuals. For instance, in cluster-allocated studies, clusters are often studied at two or more time-points (periods) with different collections of individuals contributing to the data collected at each time-point.

*Was there a comparison?*

Typically, researchers compare two or more groups that receive different interventions; the groups may be studied over the same time period, or over different time periods (see below). Sometimes researchers compare outcomes in just one group but at two time-points. It is also possible that researchers may have done both, i.e. studying two or more groups and measuring outcomes at more than one time-point.

*Were participants/clusters allocated to groups by?*

These items aim to describe how groups were formed. None will apply if the study does not compare two or more groups of subjects. The information is often not reported or is difficult to find in a paper. The items provided cover the main ways in which groups may be formed. More than one option may apply to a single study, although some options are mutually exclusive (i.e. a study is either randomized or not).

2019, 2024 by BMJ. Protected by copyright.

1  
2  
3  
4 Randomization: Allocation was carried out on the basis of truly random sequence. Such studies are covered by the standard guidance  
5 elsewhere in this *Handbook*. Check carefully whether allocation was adequately concealed until subjects were definitively recruited.  
6  
7 Quasi-randomization: Allocation was done on the basis of a pseudo-random sequence, e.g. odd/even hospital number or date of birth,  
8 alternation. Note: when such methods are used, the problem is that allocation is rarely concealed. These studies are often included in  
9 systematic reviews that only include randomized trials, using assessment of the risk of bias to distinguish them from properly randomized  
10 trials.  
11  
12 By other action of researchers: This is a catch-all category and further details should be noted if the researchers report them. Allocation  
13 happened as the result of some decision or system applied by the researchers. For example, subjects managed in particular 'units' of  
14 provision (e.g. wards, general practices) were 'chosen' to receive the intervention and subjects managed in other units to receive the control  
15 intervention.  
16  
17 Time differences: Recruitment to groups did not occur contemporaneously. For example, in a historically controlled study subjects in the control  
18 group are typically recruited earlier in time than subjects in the intervention group; the intervention is then introduced and subjects receiving  
19 the intervention are recruited. Both groups are usually recruited in the same setting. If the design was under the control of the researchers,  
20 both this option and 'other action of researchers' must be ticked for a single study. If the design 'came about' by the introduction of a new  
21 intervention, both this option and 'treatment decisions' must be ticked for a single study.  
22  
23 Location differences: Two or more groups in different geographic areas were compared, and the choice of which area(s) received the  
24 intervention and control interventions was not made randomly. So, both this option and 'other action of researchers' could be ticked for a  
25 single study.  
26  
27 Treatment decisions: Intervention and control groups were formed by naturally occurring variation in treatment decisions. This option is  
28 intended to reflect treatment decisions taken mainly by the clinicians responsible; the following option is intended to reflect treatment  
29 decisions made mainly on the basis of subjects' preferences. If treatment preferences are uniform for particular provider 'units', or switch  
30 over time, both this option and 'location' or 'time' differences should be ticked.  
31  
32 Patient preferences: Intervention and control groups were formed by naturally occurring variation in patients' preferences. This option is  
33 intended to reflect treatment decisions made mainly on the basis of subjects' preferences; the previous option is intended to reflect treatment  
34 decisions taken mainly by the clinicians responsible.  
35  
36 On the basis of outcome: A group of people who experienced a particular outcome of interest were compared with a group of people who did  
37 not, i.e. a case-control study. Note: this option should be ticked for papers that report analyses of *multiple risk factors for a particular*  
38 *outcome* in a large series of subjects, i.e. in which the total study population is divided into those who experienced the outcome and those  
39 who did not. These studies are much closer to nested case-control studies than cohort studies, even when longitudinal data are collected  
40 prospectively for consecutive patients.  
41  
42 Additional options for cluster-allocated studies.  
43  
44 Location differences: see above.  
45  
46

1  
2  
3 Policy/public health decisions: Intervention and control groups were formed by decisions made by people with the responsibility for  
4 implementing policies about public health or service provision. Where such decisions are coincident with clusters, or where such people are  
5 the researchers themselves, this item overlaps with 'other action of researchers' and 'cluster preferences'.

6 Cluster preferences: Intervention and control groups were formed by naturally occurring variation in the preferences of clusters, e.g.  
7 preferences made collectively or individually at the level of the cluster entity.

8  
9 *Which parts of the study were prospective?*

10 These items aim to describe which parts of the study were conducted prospectively. In a randomized controlled trial, all four of these items  
11 would be prospective. For NRS it is also possible that all four are prospective, although inadequate detail may be presented to discern this,  
12 particularly for generation of hypotheses. In some cohort studies, participants may be identified, and have been allocated to treatment  
13 retrospectively, but outcomes are ascertained prospectively.

14 *On what variables was comparability of groups assessed?*

15 These questions should identify 'before-and-after' studies. Baseline assessment of outcome variables is particularly useful when outcomes are  
16 measured on continuous scales, e.g. healthstatus or quality of life.

17 *Response options*

18 Try to use only 'Yes', 'No' and 'Can't tell' response options. 'N/a' should be used if a study does not report a comparison between groups.  
19  
20  
21

22 Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: Including non-randomized studies. In: Higgins JPT, Green S (editors), *Cochrane Handbook for*  
23 *Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [www.handbook.cochrane.org](http://www.handbook.cochrane.org).  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

# Reporting checklist for protocol of a systematic review.

Based on the PRISMA-P guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-P reporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. *Syst Rev.* 2015;4(1):1.

		Reporting Item	Page Number
Identification	<a href="#">#1a</a>	Identify the report as a protocol of a systematic review	1
Update	<a href="#">#1b</a>	If the protocol is for an update of a previous systematic review, identify as such	n/a not an update
	<a href="#">#2</a>	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Contact	<a href="#">#3a</a>	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	<a href="#">#3b</a>	Describe contributions of protocol authors and identify the guarantor of the review	10
	<a href="#">#4</a>	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	n/a not an amendment

1	Sources	<a href="#">#5a</a>	Indicate sources of financial or other support for the review	10
2				
3				
4	Sponsor	<a href="#">#5b</a>	Provide name for the review funder and / or sponsor	10
5				
6				
7	Role of sponsor or funder	<a href="#">#5c</a>	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	n/a- has no funder
8				
9				
10				
11	Rationale	<a href="#">#6</a>	Describe the rationale for the review in the context of what is already known	3-5
12				
13				
14				
15	Objectives	<a href="#">#7</a>	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	5
16				
17				
18				
19				
20	Eligibility criteria	<a href="#">#8</a>	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6
21				
22				
23				
24				
25				
26				
27	Information sources	<a href="#">#9</a>	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	6
28				
29				
30				
31				
32				
33				
34	Search strategy	<a href="#">#10</a>	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	6-7
35				
36				
37				
38				
39	Study records - data management	<a href="#">#11a</a>	Describe the mechanism(s) that will be used to manage records and data throughout the review	7
40				
41				
42				
43	Study records - selection process	<a href="#">#11b</a>	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	7
44				
45				
46				
47				
48				
49				
50	Study records - data collection process	<a href="#">#11c</a>	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	7
51				
52				
53				
54				
55				
56	Data items	<a href="#">#12</a>	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned	7- 8
57				
58				
59				
60				

data assumptions and simplifications

1			
2			
3	Outcomes and	<a href="#">#13</a>	List and define all outcomes for which data will be sought, 5,9
4	prioritization		including prioritization of main and additional outcomes,
5			with rationale
6			
7			
8	Risk of bias in	<a href="#">#14</a>	Describe anticipated methods for assessing risk of bias of 8-9
9	individual studies		individual studies, including whether this will be done at
10			the outcome or study level, or both; state how this
11			information will be used in data synthesis
12			
13			
14	Data synthesis	<a href="#">#15a</a>	Describe criteria under which study data will be 9
15			quantitatively synthesised
16			
17			
18		<a href="#">#15b</a>	If data are appropriate for quantitative synthesis, describe n/a
19			planned summary measures, methods of handling data
20			and methods of combining data from studies, including
21			any planned exploration of consistency (such as I <sup>2</sup> ,
22			Kendall's $\tau$ )
23			
24			
25			
26			
27		<a href="#">#15c</a>	Describe any proposed additional analyses (such as 9
28			sensitivity or subgroup analyses, meta-regression)
29			
30			
31		<a href="#">#15d</a>	If quantitative synthesis is not appropriate, describe the 9
32			type of summary planned
33			
34	Meta-bias(es)	<a href="#">#16</a>	Specify any planned assessment of meta-bias(es) (such 8-9
35			as publication bias across studies, selective reporting
36			within studies)
37			
38			
39			
40	Confidence in	<a href="#">#17</a>	Describe how the strength of the body of evidence will be 8-9
41	cumulative		assessed (such as GRADE)
42	evidence		
43			
44			

The PRISMA-P checklist is distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

# BMJ Open

## Health promotion at the workplace setting: a protocol for a systematic review of effectiveness and sustainability of current practice in low- and middle- income countries.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027050.R1
Article Type:	Protocol
Date Submitted by the Author:	02-Apr-2019
Complete List of Authors:	Wanjau, Mary; Griffith University School of Medicine, ; School of Nursing, University of Nairobi, Kenya, Zapata-Diomed, Belen; Griffith University School of Medicine Veerman, Lennert; Griffith University, School of Medicine; The University of Queensland, School of Public Health
<b>Primary Subject Heading</b>:	Public health
Secondary Subject Heading:	Occupational and environmental medicine
Keywords:	PUBLIC HEALTH, Health Promotion, sustainability, workplace, effectiveness, low- and middle- income countries

SCHOLARONE™  
Manuscripts



**Title**

Health promotion at the workplace setting: a protocol for a systematic review of effectiveness and sustainability of current practice in low- and middle- income countries.

**Corresponding Author**

Mary Njeri Wanjau

School of Medicine, Gold Coast Campus, Griffith University

170 Kessels Road, Nathan. Brisbane, Queensland 4111, Australia.

[mary.wanjau@griffithuni.edu.au](mailto:mary.wanjau@griffithuni.edu.au)

+61 (0) 484274134

**Co- authors**

Dr. Belen Zapata- Diomedi

School of Medicine, Griffith University, QLD 4222, Australia.

Gold Coast campus, Parklands Drive, Southport, QLD, 4222

[b.zapatadiomedi@griffith.edu.au](mailto:b.zapatadiomedi@griffith.edu.au)

Professor Lennert Veerman

School of Medicine, Griffith University, QLD 4222, Australia.

Gold Coast campus, Parklands Drive, Southport, QLD, 4222

[l.veerman@griffith.edu.au](mailto:l.veerman@griffith.edu.au)

**Word Count**

**2845**

# Health promotion at the workplace setting: a protocol for a systematic review of effectiveness and sustainability of current practice in low- and middle- income countries.

## ABSTRACT

### Introduction

LMICs are experiencing a growing disease burden due to NCDs. Changing behavioural practices such as, diets high in saturated fat, salt and sugar and sedentary lifestyles, have been associated with the increase in NCDs. Health promotion at the workplace setting is considered effective in the fight against NCDs and has been reported to yield numerous benefits. However, there is a need to generate evidence on the effectiveness and sustainability of WHP practice specific to LMICs. We aim to synthesize the current literature on WHP in LMICs focusing on interventions effectiveness and sustainability.

### Methods and analysis

We will conduct a systematic review of published studies from LMICs up to the 31<sup>st</sup> of March 2019. We will search the following databases: EMBASE, MEDLINE, PubMed, Web of Science, Scopus, ProQuest, and CINAHL. Two reviewers will independently screen potential articles for inclusion and disagreements will be resolved by consensus. We will appraise the quality and risk of bias of included studies using two tools from the Cochrane handbook for systematic reviews of interventions. We will present a narrative overview and assessment of the body of evidence derived from the comprehensive review of the studies. The reported outcomes will be summarised by study design, duration, intensity / frequency of intervention delivery, and by the six priority health promotion action areas set out in the Ottawa Charter. We will conduct a thematic analysis to identify the focus areas of current interventions. This systematic review protocol has been prepared according to the Preferred Reporting Items for Systematic reviews and Meta- analyses for Protocols (PRISMA-P) 2015 statement.

### Ethics and dissemination

This study does not require ethics approval. We will disseminate the results of this review through peer-reviewed publications and conference presentations.

**Trial registration number:** (PROSPERO: CRD42018110853).

### Keywords

Health promotion, workplace, systematic review, effectiveness, sustainability, LMICs.

### Strengths and limitations of this study

- This will be a comprehensive review that examines multiple workplaces, across various industries in LMICs.

- The review search dates and search strategy will ensure a comprehensive search for relevant articles.
- The methods of this review have been outlined in a protocol to guard against arbitrary decision making in the review process.
- Our search strategy is restricted by language; studies included will be limited to those in English.
- The inclusion of studies with diverse study designs, intervention types and workplace settings makes this a broad, heterogeneous study; this may limit the depth of the analysis.

## INTRODUCTION

### Rationale

Globally, 41 million deaths (71% of all deaths) were due to non-communicable diseases (NCDs) [1]. The majority of these deaths were caused by: cardiovascular disease (44%); cancer (22%); chronic respiratory disease (9%); and diabetes (4%) [1]. In low- and middle- income countries (LMICs) 85% of premature deaths are attributable to NCDs [2]. In 2014, the World Health Organisation (WHO) estimated a 17% increase of deaths from NCDs globally and a 27% increase for the African region, equivalent to 28 million additional deaths by 2030 [3]. In sub-Saharan Africa (SSA) region, where majority of the LMICs are located, the WHO [4] estimated that by 2020, NCDs will be as prevalent as communicable diseases. Already, NCDs are the main cause of adult deaths in Mauritius, Namibia and Seychelles [3].

The leading risks factors associated with the global increase in mortality are high blood pressure (responsible for 13% of death globally), tobacco use (9%), high blood glucose (6%), physical inactivity (6%), and overweight and obesity (5%) [5]. Changes in lifestyle; adoption of sedentary behaviours and nutrition transition have been identified as some of the modifiable risk factors that increase the risk of NCDs [2]. The reversal or mitigation of this trend calls for the application of effective principles and practices of health promotion [6] and the mainstreaming of health promotion [7]. The current WHO strategy towards the prevention of NCDs incorporates the reduction of health risks and promotion of healthy lifestyles through health promotion [8].

Health promotion is described as “the process that enables people to increase control over (health determinants), and to improve their health” [9]. The 1997 Jakarta declaration affirmed

1  
2  
3 that health promotion strategies were indeed effective in addressing health risk factors [10],  
4 particularly lifestyle related risk factors which can be modified to prevent disease [4].

5  
6 Globally, the health promotion approach has been adopted by many countries including the  
7 LMICs. For instance, Nyamwaya [11] points out that the use of health promotion as a means  
8 of increasing societal responsibility for health now exists in all African countries. Laws and  
9 policies that facilitate adoption of healthy lifestyles and disease prevention such as tobacco  
10 legislation, have been put in place [11]. A focus on settings for health promotion has enabled  
11 the creation of supportive environments through the development of relevant, practical health  
12 promotion interventions that address a full range of health determinants at each setting [12].  
13 The introduction of the settings approach for health promotion followed the 1986 Ottawa  
14 Charter's declaration that "health is created and lived by people within the settings of their  
15 everyday life, where they learn, work, play and love"[9]. The settings approach has translated  
16 to the utilisation of "the health potentials inherent in the social and institutional settings of  
17 everyday life" [13]. Settings identified in the Ottawa charter included: prisons, schools,  
18 universities, market places, hospitals, islands, districts, cities, regions and workplaces [9].

19  
20 The workplace as a health promotion setting presents an opportunity to reach many people  
21 within the adult population [14]. The working population is one that would not normally be  
22 engaged in organised health improvement initiatives [15]. WHO has estimated that workers are  
23 estimated to represent half of the world's population [16] and majority of them spend a  
24 substantial portion of their waking hours at work [17]. Workplace health promotion (WHP)  
25 interventions are defined as employer initiatives directed at protecting the health of employees  
26 and thereby improving their productivity [18]. The Center for Disease Control and Prevention  
27 [19] has described the three components to comprehensive WHP programs as: screening,  
28 lifestyle or risk factor management, and disease management. Workplaces may implement  
29 programs that include one component or a combination of components. Examples of screening  
30 programs include blood pressure and body weight measurement, and blood cholesterol level  
31 assessment [20]. The majority of the WHP programs target lifestyle or risk factor management  
32 at the individual level. Examples of these include: physical activity and nutrition programs [21,  
33 22], reduction in smoking [23, 24], and use of stairs [25].

34  
35 WHP contributes to improvement of employee health and can help contain the current epidemic  
36 of lifestyle-related diseases [26]. When properly designed and implemented, WHP  
37 interventions have been associated with multiple benefits. For instance, in a systematic review  
38 of literature carried out by Cancelliere, Cassidy [27], the results from 21% of the studies show  
39 preliminary evidence that WHP programs can positively affect presenteeism. Authors of a  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 review that looked at WHP interventions for smoking cessation tested in controlled studies  
4 conclude that they found strong evidence that interventions which target individual smokers  
5 increase the likelihood of quitting smoking [28]. A prospective cohort study that aimed to  
6 evaluate the impact of a 6- year WHP program reported a decrease in systolic blood pressure  
7 in the hypertension subgroup [29]. In an evaluation of a WHP program, Oberlinner, Lang [20]  
8 demonstrate that the program yielded benefits in reduction of employee's body mass index.  
9 Results from a cluster randomised controlled trial investigating effectiveness of a WHP  
10 intervention showed that there were positive changes in job performance and psychological  
11 health of the employees [30].”

12  
13 It is notable that reviews for health promotion interventions have limited their focus to  
14 individual level interventions, leaving out interventions that focus on environmental, structural  
15 and social determinants of health [31, 32]. With limited research on interventions focusing on  
16 multiple health determinants, employers have also shown reluctance to offer sufficiently  
17 comprehensive WHP programs because they are not fully persuaded of their benefits, and they  
18 also contend that there are few best practices for them to emulate [15, 33]. Moreover, most of  
19 the published research in WHP has been reported from high- income countries [33] and there  
20 is scarcity of WHP reported in the LMICs [29]. There is a gap in the provision of evidence-  
21 based health promotion interventions at the workplace. This review will yield a narrative  
22 overview and assessment of the body of evidence. The results of this review will provide  
23 additional information to guide strategic WHP choices and help identify “best buy  
24 interventions”. Sustainability of WHP programs refers to the continuation of interventions or  
25 the effects [34]. Some studies have sighted employee participation rates as an example for  
26 indication of sustainability of the WHP interventions [35, 36]. There is limited information on  
27 the long-term effectiveness and continuation of the WHP programs [34, 36].

28  
29 Overall, a systematic review that synthesizes multiple published studies on WHP from LMICs  
30 will provide a comprehensive summary of evidence available in WHP practice in these  
31 countries. Like the publication of primary research studies mentioned earlier, most of the  
32 literature reviews carried out on WHP also focus on studies done in high- income countries  
33 [37-39]. Results from this review will provide preliminary evidence for WHP effectiveness and  
34 sustainability specific to LMICs. Such evidence will facilitate the scaling up of the  
35 implementation of effective, feasible interventions within LMICs. We therefore propose to  
36 carry out a systematic review that aims to synthesise published studies on current WHP practice  
37 in LMICs countries focusing on effectiveness and sustainability of the interventions.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Objective

To assess the effectiveness and sustainability of interventions for health promotion in the workplace setting in LMICs.

We aim to address the following questions:

1. How effective are interventions for health promotion at the workplace setting in LMICs?
2. How sustainable are interventions for health promotion at the workplace setting in LMICs?

## METHODS

This review protocol is registered on the International prospective register of systematic reviews (PROSPERO: CRD42018110853). The review will be prepared according to the Preferred Reporting Items for Systematic reviews and Meta-Analysis Protocols (PRISMA-P) 2015 statement [40].

## Inclusion Criteria

- a) Population: This review will include studies done in adult populations; 18 years of age and above, within the workplace settings in LMICs.
- b) Intervention characteristics: interventions for health promotion at the workplace setting. Study designs: all study designs will be included since WHP interventions are evaluated using a wide variety of approaches and study designs [41-43].  
Publication status: published studies whose full text is publicly available. We will review the reference lists from past reviews for suitable studies that would meet the inclusion criteria. Duplicate publications of the same material will be excluded. For studies published in multiple papers, the most recent version will be considered.  
Timeline: Studies published from LMICs up to 31<sup>st</sup> of March 2019.  
Language: English.
- c) Comparison: Studies on WHP will present multiple research designs. An intervention to promote health at the workplace will be compared with no intervention. To help answer our research questions, other comparisons involving interventions will be assessed on a case to case basis as encountered in the literature.
- d) Outcomes measured either objectively or subjectively will be included in the review. This will include primary outcomes; employee participation rates, duration of intervention, objectively or subjectively measured effects of the intervention on

employee's physical, mental, financial or social health measures. As a secondary outcome, operational indicators and factors for sustainability will be considered.

### Exclusion Criteria

Workplace related studies that do not report on WHP interventions will be excluded; for example, studies reporting on a standalone aspect such as occupational safety and health, hospitals or treatment.

### Data Sources and Search Strategy

We will search the following databases: Excerpta Medica Database (Embase), Medical Literature Analysis and Retrieval System Online (MEDLINE), PubMed, Web of Science, Scopus, ProQuest, Cumulative Index to Nursing and Allied Health Literature (CINAHL).

Table 1 shows the search strategy that we will use. We will adapt the strategy to the different databases.

Table 1 Search strategy

#### Search terms

"Workplace" OR "occupational" OR "worksite" OR "organi\*ational" OR "industrial" OR "work" OR "worker" OR "employee"

AND

"Health\*" OR "health promotion" OR "Wellness" OR "Well-being" "wellbeing" OR "health management" OR " Health protection"

AND

"Program\*" OR "framework" OR "model" OR "intervention" OR "initiative"

AND

"Afghanistan" OR "Albania" OR "Algeria" OR "American Samoa" OR "Angola" OR "Armenia" OR "Azerbaijan" OR "Bangladesh" OR "Belarus" OR "Belize" OR "Benin" OR "Bhutan" OR "Bolivia" OR "Bosnia and Herzegovina" OR "Botswana" OR "Brazil" OR "Bulgaria" OR "Burkina Faso" OR "Burundi" OR "Cabo Verde" OR "Cambodia" OR "Cameroon" OR "Central African Republic" OR "Chad" OR "China" OR "Colombia" OR "Comoros" OR "Democratic Republic of Congo" OR "Congo" OR "Costa Rica" OR "Cote d'Ivoire" OR "Ivory Coast" OR "Cuba" OR "Djibouti" OR "Dominica" OR "Dominican Republic" OR "Ecuador" OR "Egypt" OR "Arab Republic" OR "El Savador" OR "Equatorial Guinea" OR "Eritrea" OR "Eswatini" OR "Ethiopia" OR "Fiji" OR "Gabon"

OR “The Gambia” OR “Georgia” OR “Ghana” OR “Grenada” OR “Guatemala” OR “Guinea” OR “Guinea Bissau” OR “Guyana” OR “Haiti” OR “Honduras” OR “India” OR “Indonesia” OR “Iran” OR “Islamic Republic” OR “Iraq” OR “Jamaica” OR “Jordan” OR “Kazakhstan” OR “Kenya” OR “Kiribati” OR “Democratic People’s Republic of Korea” OR “Korea” OR “Kosovo” OR “Kyrgyz Republic” OR “Lao PDR” OR “Lebanon” OR “Lesotho” OR “Liberia” OR “Libya” OR “Madagascar” OR “Malawi” OR “Malaysia” OR “Maldives” OR “Mali” OR “Marshall Islands” OR “Mauritania” OR “Mauritius” OR “Mexico” OR “Micronesia” OR “Moldova” OR “Mongolia” OR “Montenegro” OR “Morocco” OR “Mozambique” OR “Myanmar” OR “Namibia” OR “Nauru” OR “Nepal” OR “Nicaragua” OR “Niger” OR “Nigeria” OR “North Macedonia” OR “Pakistan” OR “Papua New Guinea” OR “Paraguay” OR “Peru” OR “Philippines” OR “Romania” OR “Russian Federation” OR “Rwanda” OR “Samoa” OR “Sao Tome and Principe” OR “Senegal” OR “Serbia” OR “Sierra Leone” OR “Solomon Islands” OR “Somalia” OR “South Africa” OR “South Sudan” OR “Sri Lanka” OR “St Lucia” OR “St Vincent and the Grenadines” OR “Sudan” OR “Suriname” OR “Syrian Arab Republic” OR “Tajikistan” OR “Tanzania” OR “Thailand” OR “Timor-Leste” OR “Togo” OR “Tonga” OR “Tunisia” OR “Turkey” OR “Turkmenistan” OR “Tuvalu” OR “Uganda” OR “Ukraine” OR “Uzbekistan” OR “Vanuatu” OR “Venezuela” OR “Vietnam” OR “West Bank of Gaza” OR “Yemen” OR “Zambia” OR “Zimbabwe” OR Africa OR “sub-Saharan Africa” OR “low and middle income countr\*” OR “low income countr\*” OR “Low OR middle income countr\*” OR “Low and middle income countr\*” OR “LMIC\*” OR “developing country” OR “underdeveloped country” OR “resource limited”

### Grey literature

To allow for the inclusion of as much evidence as possible, we will use Google web search ([www.google.com](http://www.google.com)) to look for grey literature. We will contact the first and senior author of included articles for relevant material. We will do this through email communication. **Study**

### Records

#### Data Management

We will import all identified studies to EndNote software where duplicate records will be identified and excluded from record. In our study selection process, we will be guided by the inclusion criteria. We will use Rayyan QCRI [44], an internet based program to assist the screening and selection of studies.



## Screening

Two reviewers (MW and BZ) will independently select all studies that meet the inclusion criteria. The reviewers will screen the titles and abstracts of the studies for relevance based on the criteria set. They will then screen the full texts of potential eligible studies for inclusion and relevance. Any disagreements will be resolved by consensus. The details of the excluded studies outlining reasons for exclusion will be documented and presented in a flow chart.

## Data Extraction

Using a predetermined data extraction sheet, two reviewers will independently extract data from final full texts of eligible studies and any inconsistencies will be resolved by consensus.

## Data Items

We will extract the following data from our final selection: details of publication (author, author country of affiliation, year of publication, title of article, name of journal study published in), geographical location of intervention, study context (workplace/ industry type, single or multiple organisations studied), subjects of research (role/description of target population, if study is gender specific, employment type of participants, profession), aim of the study, program/intervention priority area focus, sustainability aspects of program, methods, study outcomes, study conclusions, limitations and future research areas proposed.

## Risk of Bias and Quality Appraisal

Two reviewers will independently rate the quality and risk of bias in included studies using two tools from Cochrane handbook for systematic reviews of interventions. To assess the quality of studies included, the reviewers will use the criteria from Cochrane handbook for systematic reviews on international version 5.1.0 [45]. To assess the risk of bias, the reviewers will use the Cochrane tool (table 2) commonly used for random controlled trials. This will be adapted to this review to accommodate the multiple research designs anticipated in the included studies. The adaptation will be done as per the guidelines and criteria for judging risk of bias in the 'risk of bias' assessment tool [46]. We will assign a judgement of 'low', 'high' or 'unclear risk' of bias in the review authors' judgement column. Additional categories indicating either uncertainty or lack of information over the potential for bias will be incorporated.

For all non- randomised studies, we will incorporate an assessment of risk of bias due to confounders. We will compile a list of confounders and determine which of these confounders were considered in the selected studies. The assessment will include determining if the most important confounders were considered, how precisely each confounder was measured,

whether they were distributed similarly in intervention and control cohorts, how carefully they were controlled for and how the researchers controlled for confounding [45].

Towards the detection of reporting bias, the authors will use funnel plots to demonstrate the intervention estimates from individual studies against a measure of each study's size.

Table 2 The Cochrane tool for assessing risk of bias		
Domain	Support for Judgement	Review authors' judgement
<b>Selection bias</b>		
Random sequence generation: selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence.		
Allocation concealment: selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment.		
<b>Performance bias</b>		
Blinding or participants and personnel: performance bias due to knowledge of the allocated interventions by participants and personnel during the study.		
Blinding of outcome assessment: detection bias due to knowledge of the allocated interventions by outcome assessors.		
<b>Attrition bias</b>		
Incomplete outcome data: attrition bias due to amount, nature or handling of incomplete outcome data.		
<b>Reporting bias</b>		
Selective reporting: reporting bias due to selective outcome reporting.		
<b>Other bias</b>		
Bias due to problems not covered elsewhere in the table.		

## Data Synthesis

We will present a narrative overview and assessment of the body of evidence derived from the comprehensive review of the included studies. The studies will be presented and described by geographical region, regional spread of study authors, number of studies per year, journals that have published these studies. Additional characteristics of included studies will include; study design, duration of study, type of workplaces setting, and description of research participants and intervention, study outcomes and any additional notes by the authors.

The summary assessment of risk of bias will be considered for each important outcome within each study (across domains) and across studies presented in summary tables. We will use the summaries to make judgements about the quality of evidence. We will create additional tables listing the identified confounders as columns and the studies as rows, indicating the results of assessments of each confounder for every study. We will also develop a table of comparisons and outcomes. A comparison of results will be done between results from studies assessed at high or unclear risk of bias and from those studies at low risk of bias. Comparison will further be drawn between outcomes for the various study designs, durations of delivery for each study, frequency of intervention delivery reported, and priority health promotion action area that each WHP program focuses on. The six health promotion priority areas outlined in the Ottawa Charter [9] will be applied.

Assessment for sustainability will be adopted from the conceptual frameworks developed by Shediac-Rizkallah and Bone [47] and adopted by Cochrane handbook for systematic reviews in public health and health promotion. The operational indicators that will be assessed will be categorised as follows; maintenance of health benefits achieved through an initial program, level of institutionalisation of a program within an organisation and measures of capacity building in the workplace setting. To evaluate specific conditions or strategies that favour sustainability in the LMICs context, a criterion assessing three groups of factors will be applied; project design and implementation factors, factors within the organisational setting and factors in the broader community environment such as cultural factors [47].

Additionally, the reviewers will carry out a thematic analysis to present and discuss the main themes across different workplace types, time periods and geographical distribution of included studies. In addition to the manual data entry and summary, we will complement this analysis with the use of Leximancer Version 4 software.

## Patient and Public Involvement

We will not involve patients and the public in this review.

## Reporting this review

1  
2  
3 We will report the systematic review according to the checklist of items to include when  
4 reporting a systematic review as per the PRISMA 2009 statement [48]. We will present a flow  
5 diagram to show the study selection process, specifying reasons for exclusion at each stage.  
6  
7 The study quality appraisal tool will be availed as online supplementary material.  
8  
9

### 10 **Potential amendments**

11 In case of any changes to this protocol, we will outline the details of the changes in the final  
12 report. However, no further amendments to this protocol are foreseen.  
13  
14

### 15 **Conclusion**

16 To heed to the WHO's clarion call to implement and scale-up effective health promotion  
17 interventions in Africa [3], there is a need to assess what has been effective and sustainable in  
18 the context of the workplace setting. There is need to "...establish what has worked...and what  
19 should be done here and now, to improve the health of the people in Africa" [3] and the rest of  
20 the LMICs.  
21  
22

23 Previous reviews on WHP focused on the effectiveness of specific interventions; for example,  
24 on physical activity [49, 50], nutrition promotion [51] and smoking cessation [28]. Through  
25 this comprehensive review, we will provide new insights by presenting a holistic outline of  
26 current WHP practice in LMICs, with a focus on effectiveness and sustainability.  
27  
28  
29  
30  
31

### 32 **Ethics and dissemination**

33 Since systematic reviews are based on available published data, this review will therefore not  
34 require any formal ethical approval. We will disseminate the results of this systematic review  
35 through peer-reviewed publications and conference presentations.  
36  
37  
38  
39  
40

### 41 **Authors' Contributions**

42 MNW conceived the paper and wrote the first draft. BZD and JLV provided revisions to the  
43 manuscript. All authors read and approved the final manuscript. MNW is the guarantor of the  
44 review.  
45  
46  
47

### 48 **Data sharing Statement**

49 All data for this manuscript are included in the submission.  
50

### 51 **Funding Statement**

52 This research received no specific grant from any funding agency in the public, commercial or  
53 not-for profit sectors.  
54  
55

### 56 **Competing interests Statement**

57 None declared.  
58  
59

### 60 **REFERENCES**

1. World Health Organisation. *World Health Statistics*. 2018 [Access date: 26th November 2018]; Available from: [http://www.who.int/gho/mortality\\_burden\\_disease/life\\_tables/en/](http://www.who.int/gho/mortality_burden_disease/life_tables/en/).
2. WHO. *Non communicable diseases*. 2019 [Access date: 20th March 2019]; Available from: <https://www.who.int/en/news-room/fact-sheets/detail/noncommunicable-diseases>.
3. WHO. *The African Regional Health Report: The Health of the People*. 2014; Available from: [www.who.int/bulletin/africanhealth/en](http://www.who.int/bulletin/africanhealth/en).
4. WHO. *Chronic diseases and health promotion: Preventing chronic diseases: a vital investment*. 2005; Available from: [http://www.who.int/chp/chronic\\_disease\\_report/contents/foreword.pdf?ua=1](http://www.who.int/chp/chronic_disease_report/contents/foreword.pdf?ua=1).
5. WHO. *Health Promotion: 7th Global Conference on Health Promotion, Nairobi Call to Action*. 2009a; Available from: <http://www.who.int/healthpromotion/conferences/7gchp/en/>.
6. K.A. Sampson, U., M. Amuyunzu-Nyamongo, and G. Mensah, *Health Promotion and Cardiovascular Disease Prevention in Sub-Saharan Africa*. Vol. 56. 2013. 344-355.
7. WHO. *Global Health Risks*. 2009b; Available from: [www.who.int/healthinfo/global\\_burden\\_disease/GlobalHealthRisks\\_report\\_full.pdf](http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf).
8. WHO. *Noncommunicable diseases and their risk factors*. Prevention of noncommunicable diseases 2019 [Access date: 25th March 2019]; Available from: <https://www.who.int/ncds/prevention/introduction/en/>.
9. WHO. *The Ottawa Charter for Health promotion: an International Conference on Health Promotion, the move towards a new public health*. 1986 [Access date: 21st November 2019]; Available from: [www.who.int/healthpromotion/conferences/previous/ottawa/en/](http://www.who.int/healthpromotion/conferences/previous/ottawa/en/).
10. WHO. *Health Promotion: Jakarta Declaration on Leading Health Promotion into the 21st Century*. 1997; Available from: <http://www.who.int/healthpromotion/conferences/previous/jakarta/declaration/en/>.
11. Nyamwaya, D., *Health promotion in Africa: strategies, players, challenges and prospects*. Health Promotion International, 2003. **18**(2): p. 85-87.
12. Nutbeam, D., *What would the Ottawa Charter look like if it were written today?* Vol. 18. 2008. 435-441.
13. Kickbusch and Ilona, *Tribute to Aaron Antonovsky—'What creates health'*. Health Promotion International, 1996. **11**(1): p. 5-6.
14. Lankford, et al., *Workplace Health: Engaging Business Leaders to Combat Obesity*. Journal of Law, Medicine & Ethics, 2013. **41**: p. 40-45.
15. Goetzel Ron Z and O.R. J, *The health and cost benefits of work site health-promotion programs*. Annu. Rev. Public Health, 2008. **29**: p. 303-323.
16. WHO. *Workers' health: global plan of action*. 2007; Available from: [http://www.who.int/occupational\\_health/WHO\\_health\\_assembly\\_en\\_web.pdf?ua=1](http://www.who.int/occupational_health/WHO_health_assembly_en_web.pdf?ua=1).
17. Conrad, P., *Health and fitness at work: A participants' perspective*. Social Science & Medicine, 1988. **26**(5): p. 545-550.
18. Harden A, et al., *A systematic review of the effectiveness of health promotion interventions in the workplace*. Occup Med (Lond), 1999. **49**(8): p. 540-8.
19. CDC. *Workplace Health Promotion*. 2019 February 8, 2019 [Access date: 30th March 2019]; Available from: <https://www.cdc.gov/workplacehealthpromotion/index.html>.
20. Oberlinner, C., et al., *[Prevention of overweight and obesity in the workplace. BASF-health promotion campaign "trim down the pounds--losing weight without losing your mind"]*. Gesundheitswesen, 2007. **69**(7): p. 385-92.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
21. Robroek, S.J.W., F.J. van Lenthe, and A. Burdorf, *The role of lifestyle, health, and work in educational inequalities in sick leave and productivity loss at work*. International archives of occupational and environmental health, 2013. **86**(6): p. 619-627.
22. Chalupka, S., *Workplace obesity prevention*. Aaohn j, 2011. **59**(5): p. 236.
23. Terry, P.E., et al., *The effectiveness of a telephone-based tobacco cessation program offered as part of a worksite health promotion program*. Popul Health Manag, 2011. **14**(3): p. 117-25.
24. O'Connell, K.A., V.L. Hosein, and J.E. Schwartz, *Thinking and/or doing as strategies for resisting smoking*. Research in Nursing & Health, 2006. **29**(6): p. 533-542.
25. Eves, F.F., et al., *A multi-component stair climbing promotional campaign targeting calorific expenditure for worksites; a quasi-experimental study testing effects on behaviour, attitude and intention*. BMC Public Health, 2012. **12**(1): p. 423.
26. Mattke S, et al., *Workplace Wellness Programs Study: Final Report*. Rand Health Q, 2013. **3**(2): p. 7.
27. Cancelliere, C., et al., *Are workplace health promotion programs effective at improving presenteeism in workers? A systematic review and best evidence synthesis of the literature*. BMC public health, 2011. **11**(1): p. 395.
28. Moher, M., et al., *Workplace interventions for smoking cessation*. Cochrane Database of Systematic Reviews, 2005(2).
29. Eng, J.Y., F.M. Moy, and A. Bulgiba, *Impact of a Workplace Health Promotion Program on Employees' Blood Pressure in a Public University*. PLoS ONE, 2016. **11**(2): p. e0148307.
30. Edwardson, C.L., et al., *Effectiveness of the stand more at (SMARt) work intervention: Cluster randomised controlled trial*. BMJ (Online), 2018. **363**.
31. Wilson, M.G., P.B. Holman, and A. Hammock, *A comprehensive review of the effects of worksite health promotion on health-related outcomes*. Am J Health Promot, 1996. **10**(6): p. 429-35.
32. Jackson, N. and E. Waters, *Criteria for the systematic review of health promotion and public health interventions*. Health Promot Int, 2005. **20**(4): p. 367-74.
33. Linnan, L., et al., *Results of the 2004 National Worksite Health Promotion Survey*. American Journal of Public Health, 2008. **98**(8): p. 1503-1509.
34. Swerissen, H. and B.R. Crisp, *The sustainability of health promotion interventions for different levels of social organization*. Health Promot Int, 2004. **19**(1): p. 123-30.
35. Robroek, S.J.W., et al., *Determinants of participation in worksite health promotion programmes: a systematic review*. International Journal of Behavioral Nutrition and Physical Activity, 2009. **6**(1): p. 26.
36. Lowensteyn, I., et al., *The Sustainability of a Workplace Wellness Program That Incorporates Gamification Principles: Participant Engagement and Health Benefits After 2 Years*. American Journal of Health Promotion, 2019: p. 0890117118823165.
37. Malik, S.H., H. Blake, and L.S. Suggs, *A systematic review of workplace health promotion interventions for increasing physical activity*. British Journal of Health Psychology, 2014. **19**(1): p. 149-180.
38. Wolfenden, L., et al., *Strategies to improve the implementation of workplace-based policies or practices targeting tobacco, alcohol, diet, physical activity and obesity*. The Cochrane Database Of Systematic Reviews, 2018. **11**: p. CD012439.
39. Freak-Poli, R.L.A., et al., *Workplace pedometer interventions for increasing physical activity*. The Cochrane Database Of Systematic Reviews, 2013(4): p. CD009209.
40. David Moher, L.S., Mike Clarke, Davina Ghersi, Alessandro Liberati, Mark Petticrew, Paul Shekelle, Lesley A Stewart and PRISMA-P Group *Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement*. 2015.

- 1
- 2
- 3
- 4 41. Baum, F., *Researching public health: behind the qualitative-quantitative*  
5 *methodological debate*. Soc Sci Med, 1995. **40**(4): p. 459-68.
- 6 42. Donner, A. and N. Klar, *Pitfalls of and controversies in cluster randomization trials*.  
7 *American Journal of Public Health*, 2004. **94**(3): p. 416-422.
- 8 43. Glasziou, P., J. Vandembroucke, and I. Chalmers, *Assessing the quality of research*.  
9 *Bmj*, 2004. **328**(7430): p. 39-41.
- 10 44. Mourad Ouzzani, H.H., Zbys Fedorowicz, and Ahmed Elmagarmid. . *Rayyan — a web*  
11 *and mobile app for systematic reviews*. 2016 [cited 2018 15th September 2018];  
12 5:210:[DOI: 10.1186/s13643-016-0384-4].
- 13 45. Reeves BC, et al., *Including non-randomized studies.*, in *Cochrane Handbook for*  
14 *Systematic Reviews of Interventions*, G.S. Higgins JPT, Editor. 2011, The Cochrane  
15 Collaboration.
- 16 46. Higgins, A., Sterne JAC *Assessing risk of bias in included studies*. 2011: Cochrane  
17 Handbook for Systematic Reviews of Interventions.
- 18 47. Shediach-Rizkallah, M.C. and L.R. Bone, *Planning for the sustainability of community-*  
19 *based health programs: conceptual frameworks and future directions for research,*  
20 *practice and policy*. Health Educ Res, 1998. **13**(1): p. 87-108.
- 21 48. Moher, D., et al., *Preferred reporting items for systematic reviews and meta-analyses:*  
22 *the PRISMA statement*. PLoS Med, 2009. **6**(7): p. e1000097.
- 23 49. Marshall, A.L., *Challenges and opportunities for promoting physical activity in the*  
24 *workplace*. Journal of science and medicine in sport / Sports Medicine Australia, 2004.  
25 **7**(1 Suppl): p. 60-66.
- 26 50. Proper, K.I., et al., *The effectiveness of worksite physical activity programs on physical*  
27 *activity, physical fitness, and health*. Clinical Journal of Sport Medicine, 2003. **13**(2):  
28 p. 106-117.
- 29 51. Janer, G., M. Sala, and M. Kogevinas, *Health promotion trials at worksites and risk*  
30 *factors for cancer*. Scandinavian Journal of Work, Environment and Health, 2002.  
31 **28**(3): p. 141-157.
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Quality Appraisal tool from *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011).

Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: Including non-randomized studies. In: Higgins JPT, Green S (editors), *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [www.handbook.cochrane.org](http://www.handbook.cochrane.org).

Developing criteria for including non-randomized studies > Table 13.2.a: List of study design features (studies with allocation to interventions at the

**Table 13.2.a: List of study design features (studies with allocation to interventions at the individual level)**

	RCT	Q-RCT	NRCT	CBA	PCS	RCS	HCT	CC	CC	XS	BA	CR/CS
<i>Was there a comparison:</i>												
Between two or more groups of participants receiving different interventions?	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	N
Within the same group of participants over time?	P	P	N	Y	N	N	N	N	N	N	Y	N
<i>Were participants allocated to groups by:</i>												
Concealed randomization?	Y	N	N	N	N	N	N	N	N	N	na	na
Quasi-randomization?	N	Y	N	N	N	N	N	N	N	N	na	na
By other action of researchers?	N	N	Y	P	N	N	N	N	N	N	na	na
Time differences?	N	N	N	N	N	N	Y	N	N	N	na	na
Location differences?	N	N	P	P	P	P	P	na	na	na	na	na
Treatment decisions?	N	N	N	P	P	P	N	N	P	na	na	na
Participants' preferences?	N	N	N	P	P	P	N	N	P	na	na	na
On the basis of outcome?	N	N	N	N	N	N	N	Y	P	na	na	na
Some other process? (specify)												
<i>Which parts of the study were prospective:</i>												
Identification of participants?	Y	Y	Y	P	Y	N	P*	N	N	P	P	P
Assessment of baseline and allocation to intervention?	Y	Y	Y	P	Y	N	P*	N	N	na	na	na
Assessment of outcomes?	Y	Y	Y	P	Y	P	P	N	N	P	P	P



Generation of hypotheses?	Y	Y	Y	Y	Y	Y	Y	Y	P	P	P	na
<i>On what variables was comparability between groups assessed:</i>												
Potential confounders?	P	P	P	P	P	P	P	P	P	P	N	na
Baseline assessment of outcome variables?	P	P	P	Y	P	P	P	P	N	N	N	na

Y=Yes; P=Possibly; P\*=Possible for one group only; N=No; na=not applicable. NB: Note that 'possibly' is used in the table to indicate cells where either 'Y' or 'N' may be the case. It should not be used as a response option when applying the checklist; if uncertain, the response should be 'can't tell' (see [Box 13.4.a](#)).

RCT=Randomized controlled trial; Q-RCT=Quasi-randomized controlled trial; NRCT=Non-randomized controlled trial; CBA=Controlled before-and-after study; PCS=Prospective cohort study; RCS=Retrospective cohort study; HCT=Historically controlled trial; NCC=Nested case-control study; CC=Case-control study; XS=Cross-sectional study; BA=Before-and-after comparison; CR/CS=Case report/Case series

Table 13.2.b: List of study design features (studies with allocation to interventions at the group

**Table 13.2.b: List of study design features (studies with allocation to interventions at the group level)**

	CIRCT	CIQ-RCT	CINRT	CITS	CChBA	ITS	ChBA	EcoXS
<i>Was there a comparison:</i>								
Between two or more groups of clusters receiving different interventions?	Y	Y	Y	Y	Y	N	N	Y
Within the same group of clusters over time?	P	P	N	Y	N	Y	Y	N
<i>Were clusters allocated to groups by:</i>								
Concealed randomization?	Y	N	N	N	N	N	N	N
Quasi-randomization?	N	Y	N	N	N	N	N	N
By other action of researchers?	N	N	Y	P	P	N	N	N
Time differences?	N	N	N	Y	Y	Y	Y	N
Location differences?	N	N	P	P	P	N	N	P
Policy/public health decisions?	Na	na	P	P	P	P	na	na
Cluster preferences?	Na	na	P	P	P	P	na	na
Some other process? (specify)								
<i>Which parts of the study were prospective:</i>								
Identification of participating clusters?	Y	Y	Y	P	P	P	P	N
Assessment of baseline and allocation to intervention?	Y	Y	Y	P	P	P	P	N

Assessment of outcomes?	Y	Y	Y	P	P	P	P	N
Generation of hypotheses?	Y	Y	Y	Y	Y	Y	Y	P
<i>On what variables was comparability between groups assessed:</i>								
Potential confounders?	P	P	P	P	P	P	P	P
Baseline assessment of outcome variables?	P	P	P	Y	Y	Y	Y	N

Note that 'cluster' refers to an entity (e.g. an organization), not necessarily to a group of participants; 'group' refers to one or more clusters; see [Box 13.4.a](#).

Note that 'possibly' is used in the table to indicate cells where *either* 'Y' or 'N' may be the case. It should not be used as a response option when applying the checklist; if uncertain, 'can't tell' should be used (see [Box 13.4.a](#)).

Y=Yes; P=Possibly; P\*=Possible for one group only; N=No; NR=Not required. CIRCT=Cluster randomized controlled trial; CIQ-RCT=Cluster quasi-randomized controlled trial; CINRT=Cluster non-randomized controlled trial; CITS=Controlled interrupted time series (Shadish 2002); CChBA=Controlled cohort before-and-after study (Shadish 2002); ITS=Interrupted time series; ChBA=Cohort before and after study (Shadish 2002); EcoXS=Ecological cross-sectional study.

**Box 13.4.a: User guide for data collection/study assessment using checklist in [Table 13.2.a](#) or [Table 13.2.b](#)**

Note: Users need to be very clear about the way in which the terms 'group' and 'cluster' are used in these tables. [Table 13.2.a](#) only refers to groups, which is used in its conventional sense to mean a number of individual participants. With the exception of allocation on the basis of outcome, 'group' can be interpreted synonymously with 'intervention group'. [Table 13.2.b](#) refers to both clusters and groups. In this table, 'clusters' are typically an organizational entity such as a family health practice, or administrative area, not an individual. As in [Table 13.2.a](#), 'group' is synonymous with 'intervention group' and is used to describe a collection of allocated units, but in [Table 13.2.b](#) these units are clusters rather than individuals. Furthermore, although individuals are nested in clusters, a cluster does not necessarily represent a fixed collection of individuals. For instance, in cluster-allocated studies, clusters are often studied at two or more time-points (periods) with different collections of individuals contributing to the data collected at each time-point.

*Was there a comparison?*

Typically, researchers compare two or more groups that receive different interventions; the groups may be studied over the same time period, or over different time periods (see below). Sometimes researchers compare outcomes in just one group but at two time-points. It is also possible that researchers may have done both, i.e. studying two or more groups and measuring outcomes at more than one time-point.

*Were participants/clusters allocated to groups by?*

These items aim to describe how groups were formed. None will apply if the study does not compare two or more groups of subjects. The information is often not reported or is difficult to find in a paper. The items provided cover the main ways in which groups may be formed. More than one option may apply to a single study, although some options are mutually exclusive (i.e. a study is either randomized or not).

6/bmjopen-2018-027050 on 22 May 2019. Downloaded from <http://bmjopen.bmj.com/>. Protected by copyright.

1  
2  
3  
4 Randomization: Allocation was carried out on the basis of truly random sequence. Such studies are covered by the standard guidance  
5 elsewhere in this *Handbook*. Check carefully whether allocation was adequately concealed until subjects were definitively recruited.  
6  
7 Quasi-randomization: Allocation was done on the basis of a pseudo-random sequence, e.g. odd/even hospital number or date of birth,  
8 alternation. Note: when such methods are used, the problem is that allocation is rarely concealed. These studies are often included in  
9 systematic reviews that only include randomized trials, using assessment of the risk of bias to distinguish them from properly randomized  
10 trials.  
11  
12 By other action of researchers: This is a catch-all category and further details should be noted if the researchers report them. Allocation  
13 happened as the result of some decision or system applied by the researchers. For example, subjects managed in particular 'units' of  
14 provision (e.g. wards, general practices) were 'chosen' to receive the intervention and subjects managed in other units to receive the control  
15 intervention.  
16  
17 Time differences: Recruitment to groups did not occur contemporaneously. For example, in a historically controlled study subjects in the control  
18 group are typically recruited earlier in time than subjects in the intervention group; the intervention is then introduced and subjects receiving  
19 the intervention are recruited. Both groups are usually recruited in the same setting. If the design was under the control of the researchers,  
20 both this option and 'other action of researchers' must be ticked for a single study. If the design 'came about' by the introduction of a new  
21 intervention, both this option and 'treatment decisions' must be ticked for a single study.  
22  
23 Location differences: Two or more groups in different geographic areas were compared, and the choice of which area(s) received the  
24 intervention and control interventions was not made randomly. So, both this option and 'other action of researchers' could be ticked for a  
25 single study.  
26  
27 Treatment decisions: Intervention and control groups were formed by naturally occurring variation in treatment decisions. This option is  
28 intended to reflect treatment decisions taken mainly by the clinicians responsible; the following option is intended to reflect treatment  
29 decisions made mainly on the basis of subjects' preferences. If treatment preferences are uniform for particular provider 'units', or switch  
30 over time, both this option and 'location' or 'time' differences should be ticked.  
31  
32 Patient preferences: Intervention and control groups were formed by naturally occurring variation in patients' preferences. This option is  
33 intended to reflect treatment decisions made mainly on the basis of subjects' preferences; the previous option is intended to reflect treatment  
34 decisions taken mainly by the clinicians responsible.  
35  
36 On the basis of outcome: A group of people who experienced a particular outcome of interest were compared with a group of people who did  
37 not, i.e. a case-control study. Note: this option should be ticked for papers that report analyses of *multiple risk factors for a particular*  
38 *outcome* in a large series of subjects, i.e. in which the total study population is divided into those who experienced the outcome and those  
39 who did not. These studies are much closer to nested case-control studies than cohort studies, even when longitudinal data are collected  
40 prospectively for consecutive patients.  
41  
42 Additional options for cluster-allocated studies.  
43  
44 Location differences: see above.  
45  
46

1  
2  
3 Policy/public health decisions: Intervention and control groups were formed by decisions made by people with the responsibility for  
4 implementing policies about public health or service provision. Where such decisions are coincident with clusters, or where such people are  
5 the researchers themselves, this item overlaps with 'other action of researchers' and 'cluster preferences'.

6 Cluster preferences: Intervention and control groups were formed by naturally occurring variation in the preferences of clusters, e.g.  
7 preferences made collectively or individually at the level of the cluster entity.

8  
9 *Which parts of the study were prospective?*

10 These items aim to describe which parts of the study were conducted prospectively. In a randomized controlled trial, all four of these items  
11 would be prospective. For NRS it is also possible that all four are prospective, although inadequate detail may be presented to discern this,  
12 particularly for generation of hypotheses. In some cohort studies, participants may be identified, and have been allocated to treatment  
13 retrospectively, but outcomes are ascertained prospectively.

14 *On what variables was comparability of groups assessed?*

15 These questions should identify 'before-and-after' studies. Baseline assessment of outcome variables is particularly useful when outcomes are  
16 measured on continuous scales, e.g. healthstatus or quality of life.

17 *Response options*

18 Try to use only 'Yes', 'No' and 'Can't tell' response options. 'N/a' should be used if a study does not report a comparison between groups.  
19  
20  
21

22 Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: Including non-randomized studies. In: Higgins JPT, Green S (editors), *Cochrane Handbook for*  
23 *Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [www.handbook.cochrane.org](http://www.handbook.cochrane.org).

# Reporting checklist for protocol of a systematic review.

Based on the PRISMA-P guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-P reporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. *Syst Rev.* 2015;4(1):1.

		Reporting Item	Page Number
Identification	<a href="#">#1a</a>	Identify the report as a protocol of a systematic review	1
Update	<a href="#">#1b</a>	If the protocol is for an update of a previous systematic review, identify as such	n/a not an update
	<a href="#">#2</a>	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Contact	<a href="#">#3a</a>	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	<a href="#">#3b</a>	Describe contributions of protocol authors and identify the guarantor of the review	10
	<a href="#">#4</a>	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	n/a not an amendment

1	Sources	<a href="#">#5a</a>	Indicate sources of financial or other support for the review	10
2				
3				
4	Sponsor	<a href="#">#5b</a>	Provide name for the review funder and / or sponsor	10
5				
6				
7	Role of sponsor or funder	<a href="#">#5c</a>	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	n/a- has no funder
8				
9				
10				
11	Rationale	<a href="#">#6</a>	Describe the rationale for the review in the context of what is already known	3-5
12				
13				
14				
15	Objectives	<a href="#">#7</a>	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	5
16				
17				
18				
19				
20	Eligibility criteria	<a href="#">#8</a>	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6
21				
22				
23				
24				
25				
26				
27	Information sources	<a href="#">#9</a>	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	6
28				
29				
30				
31				
32				
33				
34	Search strategy	<a href="#">#10</a>	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	6-7
35				
36				
37				
38				
39	Study records - data management	<a href="#">#11a</a>	Describe the mechanism(s) that will be used to manage records and data throughout the review	7
40				
41				
42				
43	Study records - selection process	<a href="#">#11b</a>	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	7
44				
45				
46				
47				
48				
49	Study records - data collection process	<a href="#">#11c</a>	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	7
50				
51				
52				
53				
54				
55				
56	Data items	<a href="#">#12</a>	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned	7- 8
57				
58				
59				
60				

data assumptions and simplifications

1			
2			
3	Outcomes and	<a href="#">#13</a>	List and define all outcomes for which data will be sought, 5,9
4	prioritization		including prioritization of main and additional outcomes,
5			with rationale
6			
7			
8	Risk of bias in	<a href="#">#14</a>	Describe anticipated methods for assessing risk of bias of 8-9
9	individual studies		individual studies, including whether this will be done at
10			the outcome or study level, or both; state how this
11			information will be used in data synthesis
12			
13			
14	Data synthesis	<a href="#">#15a</a>	Describe criteria under which study data will be 9
15			quantitatively synthesised
16			
17			
18		<a href="#">#15b</a>	If data are appropriate for quantitative synthesis, describe n/a
19			planned summary measures, methods of handling data
20			and methods of combining data from studies, including
21			any planned exploration of consistency (such as I2,
22			Kendall's $\tau$ )
23			
24			
25			
26			
27		<a href="#">#15c</a>	Describe any proposed additional analyses (such as 9
28			sensitivity or subgroup analyses, meta-regression)
29			
30			
31		<a href="#">#15d</a>	If quantitative synthesis is not appropriate, describe the 9
32			type of summary planned
33			
34	Meta-bias(es)	<a href="#">#16</a>	Specify any planned assessment of meta-bias(es) (such 8-9
35			as publication bias across studies, selective reporting
36			within studies)
37			
38			
39			
40	Confidence in	<a href="#">#17</a>	Describe how the strength of the body of evidence will be 8-9
41	cumulative		assessed (such as GRADE)
42	evidence		
43			
44			

The PRISMA-P checklist is distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

# BMJ Open

## Health promotion at the workplace setting: a protocol for a systematic review of effectiveness and sustainability of current practice in low- and middle- income countries.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027050.R2
Article Type:	Protocol
Date Submitted by the Author:	16-Apr-2019
Complete List of Authors:	Wanjau, Mary; Griffith University School of Medicine, ; School of Nursing, University of Nairobi, Kenya, Zapata-Diomedes, Belen; Griffith University School of Medicine Veerman, Lennert; Griffith University, School of Medicine; The University of Queensland, School of Public Health
<b>Primary Subject Heading</b>:	Public health
Secondary Subject Heading:	Occupational and environmental medicine, Public health
Keywords:	Health Promotion, sustainability, workplace, effectiveness, low- and middle- income countries

SCHOLARONE™  
Manuscripts



**Title**

Health promotion at the workplace setting: a protocol for a systematic review of effectiveness and sustainability of current practice in low- and middle- income countries.

**Corresponding Author**

Mary Njeri Wanjau

School of Medicine, Gold Coast Campus, Griffith University

170 Kessels Road, Nathan. Brisbane, Queensland 4111, Australia.

[mary.wanjau@griffithuni.edu.au](mailto:mary.wanjau@griffithuni.edu.au)

+61 (0) 484274134

**Co- authors**

Dr. Belen Zapata- Diomedi

School of Medicine, Griffith University, QLD 4222, Australia.

Gold Coast campus, Parklands Drive, Southport, QLD, 4222

[b.zapatadiomedi@griffith.edu.au](mailto:b.zapatadiomedi@griffith.edu.au)

Professor Lennert Veerman

School of Medicine, Griffith University, QLD 4222, Australia.

Gold Coast campus, Parklands Drive, Southport, QLD, 4222

[l.veerman@griffith.edu.au](mailto:l.veerman@griffith.edu.au)

**Word Count**

**2851**

# Health promotion at the workplace setting: a protocol for a systematic review of effectiveness and sustainability of current practice in low- and middle- income countries.

## ABSTRACT

### Introduction

Low- and middle- income countries (LMICs) are experiencing a growing disease burden due to non- communicable diseases (NCDs). Changing behavioural practices such as, diets high in saturated fat, salt and sugar and sedentary lifestyles, have been associated with the increase in NCDs. Health promotion at the workplace setting is considered effective in the fight against NCDs and has been reported to yield numerous benefits. However, there is a need to generate evidence on the effectiveness and sustainability of workplace health promotion practice specific to LMICs. We aim to synthesize the current literature on workplace health promotion in LMICs focusing on interventions effectiveness and sustainability.

### Methods and analysis

We will conduct a systematic review of published studies from LMICs up to the 31<sup>st</sup> of March 2019. We will search the following databases: EMBASE, MEDLINE, PubMed, Web of Science, Scopus, ProQuest, and CINAHL. Two reviewers will independently screen potential articles for inclusion and disagreements will be resolved by consensus. We will appraise the quality and risk of bias of included studies using two tools from the Cochrane handbook for systematic reviews of interventions. We will present a narrative overview and assessment of the body of evidence derived from the comprehensive review of the studies. The reported outcomes will be summarised by study design, duration, intensity / frequency of intervention delivery, and by the six-priority health promotion action areas set out in the Ottawa Charter. We will conduct a thematic analysis to identify the focus areas of current interventions. This systematic review protocol has been prepared according to the Preferred Reporting Items for Systematic reviews and Meta- analyses for Protocols (PRISMA-P) 2015 statement.

### Ethics and dissemination

This study does not require ethics approval. We will disseminate the results of this review through peer-reviewed publications and conference presentations.

**Trial registration number:** CRD42018110853.

### Keywords

Health promotion, workplace, systematic review, effectiveness, sustainability, LMICs.

### Strengths and limitations of this study

- This will be a comprehensive review that examines multiple workplaces, across various industries in LMICs.

- The review search dates and search strategy will ensure a comprehensive search for relevant articles.
- The methods of this review have been outlined in a protocol to guard against arbitrary decision making in the review process.
- Our search strategy is restricted by language; studies included will be limited to those in English.
- The inclusion of studies with diverse study designs, intervention types and workplace settings makes this a broad, heterogeneous study; this may limit the depth of the analysis.

## INTRODUCTION

### Rationale

In 2016, an estimated 41 million deaths globally (71% of all deaths) were due to non-communicable diseases (NCDs) [1]. The majority of these deaths were caused by: cardiovascular disease (44%); cancer (22%); chronic respiratory disease (9%); and diabetes (4%) [1]. In low- and middle- income countries (LMICs) 85% of premature deaths are attributable to NCDs [2]. In 2014, the World Health Organisation (WHO) estimated a 17% increase of deaths from NCDs globally and a 27% increase for the African region, equivalent to 28 million additional deaths by 2030 [3]. In sub-Saharan Africa (SSA) region, where majority of the LMICs are located, the WHO [4] estimated that by 2020, NCDs will be as prevalent as communicable diseases. Already, NCDs are the main cause of adult deaths in Mauritius, Namibia and Seychelles [3].

The leading risks factors associated with the global increase in mortality are high blood pressure (responsible for 13% of death globally), tobacco use (9%), high blood glucose (6%), physical inactivity (6%), and overweight and obesity (5%) [5]. Changes in lifestyle; adoption of sedentary behaviours and nutrition transition have been identified as some of the modifiable risk factors that increase the risk of NCDs [2]. The reversal or mitigation of this trend calls for the application of effective principles and practices of health promotion [6] and the mainstreaming of health promotion [7]. The current WHO strategy towards the prevention of NCDs incorporates the reduction of health risks and promotion of healthy lifestyles through health promotion [8].

Health promotion is described as “the process that enables people to increase control over (health determinants), and to improve their health” [9]. The 1997 Jakarta declaration affirmed

1  
2  
3 that health promotion strategies were indeed effective in addressing health risk factors [10],  
4 particularly lifestyle related risk factors which can be modified to prevent disease [4].

5  
6 Globally, the health promotion approach has been adopted by many countries including the  
7 LMICs. For instance, Nyamwaya [11] points out that the use of health promotion as a means  
8 of increasing societal responsibility for health now exists in all African countries. Laws and  
9 policies that facilitate adoption of healthy lifestyles and disease prevention such as tobacco  
10 legislation, have been put in place [11]. A focus on settings for health promotion has enabled  
11 the creation of supportive environments through the development of relevant, practical health  
12 promotion interventions that address a full range of health determinants at each setting [12].  
13 The introduction of the settings approach for health promotion followed the 1986 Ottawa  
14 Charter's declaration that "health is created and lived by people within the settings of their  
15 everyday life, where they learn, work, play and love"[9]. The settings approach has translated  
16 to the utilisation of "the health potentials inherent in the social and institutional settings of  
17 everyday life" [13]. Settings identified in the Ottawa charter included: prisons, schools,  
18 universities, market places, hospitals, islands, districts, cities, regions and workplaces [9].

19  
20 The workplace as a health promotion setting presents an opportunity to reach many people  
21 within the adult population [14]. The working population is one that would not normally be  
22 engaged in organised health improvement initiatives [15]. WHO has estimated that workers are  
23 estimated to represent half of the world's population [16] and majority of them spend a  
24 substantial portion of their waking hours at work [17]. Workplace health promotion (WHP)  
25 interventions are defined as employer initiatives directed at protecting the health of employees  
26 and thereby improving their productivity [18]. The Center for Disease Control and Prevention  
27 [19] has described the three components to comprehensive WHP programs as: screening,  
28 lifestyle or risk factor management, and disease management. Workplaces may implement  
29 programs that include one component or a combination of components. Examples of screening  
30 programs include blood pressure and body weight measurement, and blood cholesterol level  
31 assessment [20]. The majority of the WHP programs target lifestyle or risk factor management  
32 at the individual level. Examples of these include: physical activity and nutrition programs [21,  
33 22], reduction in smoking [23, 24], and use of stairs [25].

34  
35 WHP contributes to improvement of employee health and can help contain the current epidemic  
36 of lifestyle-related diseases [26]. When properly designed and implemented, WHP  
37 interventions have been associated with multiple benefits. For instance, in a systematic review  
38 of literature carried out by Cancelliere, Cassidy [27], the results from 21% of the studies show  
39 preliminary evidence that WHP programs can positively affect presenteeism. Authors of a  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 review that looked at WHP interventions for smoking cessation tested in controlled studies  
4 conclude that they found strong evidence that interventions which target individual smokers  
5 increase the likelihood of quitting smoking [28]. A prospective cohort study that aimed to  
6 evaluate the impact of a 6- year WHP program reported a decrease in systolic blood pressure  
7 in the hypertension subgroup [29]. In an evaluation of a WHP program, Oberlinner, Lang [20]  
8 demonstrate that the program yielded benefits in reduction of employee's body mass index.  
9 Results from a cluster randomised controlled trial investigating effectiveness of a WHP  
10 intervention showed that there were positive changes in job performance and psychological  
11 health of the employees [30].”

12  
13 It is notable that reviews for health promotion interventions have limited their focus to  
14 individual level interventions, leaving out interventions that focus on environmental, structural  
15 and social determinants of health [31, 32]. With limited research on interventions focusing on  
16 multiple health determinants, employers have also shown reluctance to offer sufficiently  
17 comprehensive WHP programs because they are not fully persuaded of their benefits, and they  
18 also contend that there are few best practices for them to emulate [15, 33]. Moreover, most of  
19 the published research in WHP has been reported from high- income countries [33] and there  
20 is scarcity of WHP reported in the LMICs [29]. There is a gap in the provision of evidence-  
21 based health promotion interventions at the workplace. This review will yield a narrative  
22 overview and assessment of the body of evidence. The results of this review will provide  
23 additional information to guide strategic WHP choices and help identify “best buy  
24 interventions”. Sustainability of WHP programs refers to the continuation of interventions or  
25 the effects [34]. Some studies have sighted employee participation rates as an example for  
26 indication of sustainability of the WHP interventions [35, 36]. There is limited information on  
27 the long-term effectiveness and continuation of the WHP programs [34, 36].

28  
29 Overall, a systematic review that synthesizes multiple published studies on WHP from LMICs  
30 will provide a comprehensive summary of evidence available in WHP practice in these  
31 countries. Like the publication of primary research studies mentioned earlier, most of the  
32 literature reviews carried out on WHP also focus on studies done in high- income countries  
33 [37-39]. Results from this review will provide preliminary evidence for WHP effectiveness and  
34 sustainability specific to LMICs. Such evidence will facilitate the scaling up of the  
35 implementation of effective, feasible interventions within LMICs. We therefore propose to  
36 carry out a systematic review that aims to synthesise published studies on current WHP practice  
37 in LMICs countries focusing on effectiveness and sustainability of the interventions.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Objective

To assess the effectiveness and sustainability of interventions for health promotion in the workplace setting in LMICs.

We aim to address the following questions:

1. How effective are interventions for health promotion at the workplace setting in LMICs?
2. How sustainable are interventions for health promotion at the workplace setting in LMICs?

## METHODS

This review protocol is registered in the PROSPERO International prospective register of systematic reviews ( Registration Number:CRD42018110853). The review will be prepared according to the Preferred Reporting Items for Systematic reviews and Meta-Analysis Protocols (PRISMA-P) 2015 statement [40].

### Inclusion Criteria

a) Population: This review will include studies done in adult populations; 18 years of age and above, within the workplace settings in LMICs.

b) Intervention characteristics: interventions for health promotion at the workplace setting. Study designs: all study designs will be included since WHP interventions are evaluated using a wide variety of approaches and study designs [41-43].

Publication status: published studies whose full text is publicly available. We will review the reference lists from past reviews for suitable studies that would meet the inclusion criteria. Duplicate publications of the same material will be excluded. For studies published in multiple papers, the most recent version will be considered.

Timeline: Studies published from LMICs up to 31<sup>st</sup> of March 2019.

Language: English.

c) Comparison: Studies on WHP will present multiple research designs. An intervention to promote health at the workplace will be compared with no intervention. To help answer our research questions, other comparisons involving interventions will be assessed on a case to case basis as encountered in the literature.

d) Outcomes measured either objectively or subjectively will be included in the review. This will include primary outcomes; employee participation rates, duration of intervention, objectively or subjectively measured effects of the intervention on employee's physical, mental, financial or social health measures. As a secondary outcome, operational indicators and factors for sustainability will be considered.

### Exclusion Criteria

Workplace related studies that do not report on WHP interventions will be excluded; for example, studies reporting on a standalone aspect such as occupational safety and health, hospitals or treatment.

### Data Sources and Search Strategy

We will search the following databases: Excerpta Medica Database (Embase), Medical Literature Analysis and Retrieval System Online (MEDLINE), PubMed, Web of Science, Scopus, ProQuest, Cumulative Index to Nursing and Allied Health Literature (CINAHL).

Table 1 shows the search strategy that we will use. We will adapt the strategy to the different databases.

Table 1 Search strategy

#### Search terms

"Workplace" OR "occupational" OR "worksite" OR "organi\*ational" OR "industrial" OR "work" OR "worker" OR "employee"

AND

"Health\*" OR "health promotion" OR "Wellness" OR "Well-being" "wellbeing" OR "health management" OR " Health protection"

AND

"Program\*" OR "framework" OR "model" OR "intervention" OR "initiative"

AND

"Afghanistan" OR "Albania" OR "Algeria" OR "American Samoa" OR "Angola" OR "Armenia" OR "Azerbaijan" OR "Bangladesh" OR "Belarus" OR "Belize" OR "Benin" OR "Bhutan" OR "Bolivia" OR "Bosnia and Herzegovina" OR "Botswana" OR "Brazil" OR "Bulgaria" OR "Burkina Faso" OR "Burundi" OR "Cabo Verde" OR "Cambodia" OR "Cameroon" OR "Central African Republic" OR "Chad" OR "China" OR "Colombia" OR "Comoros" OR "Democratic Republic of Congo" OR "Congo" OR "Costa Rica" OR "Cote d'Ivoire" OR "Ivory Coast" OR "Cuba" OR "Djibouti" OR "Dominica" OR "Dominican Republic" OR "Ecuador" OR "Egypt" OR "Arab Republic" OR "El Savador" OR "Equatorial Guinea" OR "Eritrea" OR "Eswatini" OR "Ethiopia" OR "Fiji" OR "Gabon" OR "The Gambia" OR "Georgia" OR "Ghana" OR "Grenada" OR "Guatamela" OR "Guinea" OR "Guinea Bissau" OR "Guyana" OR "Haiti" OR "Honduras" OR "India" OR "Indonesia" OR "Iran" OR "Islamic Republic" OR "Iraq" OR "Jamaica" OR "Jordan" OR "Kazakhstan" OR "Kenya" OR "Kiribati" OR "Democratic People's Republic of Korea"

OR “Korea” OR “Kosovo” OR “Kyrgyz Republic” OR “Lao PDR” OR “Lebanon” OR “Lesotho” OR “Liberia” OR “Libya” OR “Madagascar” OR “Malawi” OR “Malaysia” OR “Maldives” OR “Mali” OR “Marshall Islands” OR “Mauritania” OR “Mauritius” OR “Mexico” OR “Micronesia” OR “Moldova” OR “Mongolia” OR “Montenegro” OR “Morocco” OR “Mozambique” OR “Myanmar” OR “Namibia” OR “Nauru” OR “Nepal” OR “Nicaragua” OR “Niger” OR “Nigeria” OR “North Macedonia” OR “Pakistan” OR “Papua New Guinea” OR “Paraguay” OR “Peru” OR “Philippines” OR “Romania” OR “Russian Federation” OR “Rwanda” OR “Samoa” OR “Sao Tome and Principe” OR “Senegal” OR “Serbia” OR “Sierra Leone” OR “Solomon Islands” OR “Somalia” OR “South Africa” OR “South Sudan” OR “Sri Lanka” OR “St Lucia” OR “St Vincent and the Grenadines” OR “Sudan” OR “Suriname” OR “Syrian Arab Republic” OR “Tajikistan” OR “Tanzania” OR “Thailand” OR “Timor-Leste” OR “Togo” OR “Tonga” OR “Tunisia” OR “Turkey” OR “Turkmenistan” OR “Tuvalu” OR “Uganda” OR “Ukraine” OR “Uzbekistan” OR “Vanuatu” OR “Venezuela” OR “Vietnam” OR “West Bank of Gaza” OR “Yemen” OR “Zambia” OR “Zimbabwe” OR Africa OR “sub-Saharan Africa” OR “low and middle income countr\*” OR “low income countr\*” OR “Low OR middle income countr\*” OR “Low and middle income countr\*” OR “LMIC\*” OR “developing country” OR “underdeveloped country” OR “resource limited”

## Grey literature

To allow for the inclusion of as much evidence as possible, we will use Google web search ([www.google.com](http://www.google.com)) to look for grey literature. We will contact the first and senior author of included articles for relevant material. We will do this through email communication.

## Study Records

### Data Management

We will import all identified studies to EndNote software where duplicate records will be identified and excluded from record. In our study selection process, we will be guided by the inclusion criteria. We will use Rayyan QCRI [44], an internet based program to assist the screening and selection of studies.

### Screening

Two reviewers (MW and BZ) will independently select all studies that meet the inclusion criteria. The reviewers will screen the titles and abstracts of the studies for relevance based on the criteria set. They will then screen the full texts of potential eligible studies for inclusion and



1  
2  
3 relevance. Any disagreements will be resolved by consensus. The details of the excluded  
4 studies outlining reasons for exclusion will be documented and presented in a flow chart.  
5  
6  
7

#### 8 Data Extraction

9  
10 Using a predetermined data extraction sheet, two reviewers will independently extract data  
11 from final full texts of eligible studies and any inconsistencies will be resolved by consensus.  
12

#### 13 Data Items

14  
15 We will extract the following data from our final selection: details of publication (author,  
16 author country of affiliation, year of publication, title of article, name of journal study published  
17 in), geographical location of intervention, study context (workplace/ industry type, single or  
18 multiple organisations studied), subjects of research (role/description of target population, if  
19 study is gender specific, employment type of participants, profession), aim of the study,  
20 program/intervention priority area focus, sustainability aspects of program, methods, study  
21 outcomes, study conclusions, limitations and future research areas proposed.  
22  
23  
24  
25  
26

#### 27 Risk of Bias and Quality Appraisal

28  
29 Two reviewers will independently rate the quality and risk of bias in included studies using  
30 two tools from Cochrane handbook for systematic reviews of interventions. To assess the  
31 quality of studies included, the reviewers will use the criteria from Cochrane handbook for  
32 systematic reviews on international version 5.1.0 [45]. To assess the risk of bias, the reviewers  
33 will use the Cochrane tool (table 2) commonly used for random controlled trials. This will be  
34 adapted to this review to accommodate the multiple research designs anticipated in the included  
35 studies. The adaptation will be done as per the guidelines and criteria for judging risk of bias  
36 in the 'risk of bias' assessment tool [46]. We will assign a judgement of 'low', 'high' or  
37 'unclear risk' of bias in the review authors' judgement column. Additional categories indicating  
38 either uncertainty or lack of information over the potential for bias will be incorporated.  
39

40  
41 For all non- randomised studies, we will incorporate an assessment of risk of bias due to  
42 confounders. We will compile a list of confounders and determine which of these confounders  
43 were considered in the selected studies. The assessment will include determining if the most  
44 important confounders were considered, how precisely each confounder was measured,  
45 whether they were distributed similarly in intervention and control cohorts, how carefully they  
46 were controlled for and how the researchers controlled for confounding [45].  
47  
48  
49

50  
51 Towards the detection of reporting bias, the authors will use funnel plots to demonstrate the  
52 intervention estimates from individual studies against a measure of each study's size.  
53  
54  
55  
56  
57  
58  
59  
60

Table 2 The Cochrane tool for assessing risk of bias		
Domain	Support for Judgement	Review authors' judgement
<b>Selection bias</b>		
Random sequence generation: selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence.		
Allocation concealment: selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment.		
<b>Performance bias</b>		
Blinding of participants and personnel: performance bias due to knowledge of the allocated interventions by participants and personnel during the study.		
Blinding of outcome assessment: detection bias due to knowledge of the allocated interventions by outcome assessors.		
<b>Attrition bias</b>		
Incomplete outcome data: attrition bias due to amount, nature or handling of incomplete outcome data.		
<b>Reporting bias</b>		
Selective reporting: reporting bias due to selective outcome reporting.		
<b>Other bias</b>		
Bias due to problems not covered elsewhere in the table.		

### Data Synthesis

We will present a narrative overview and assessment of the body of evidence derived from the comprehensive review of the included studies. The studies will be presented and described by geographical region, regional spread of study authors, number of studies per year, journals that

1  
2  
3 have published these studies. Additional characteristics of included studies will include; study  
4 design, duration of study, type of workplaces setting, and description of research participants  
5 and intervention, study outcomes and any additional notes by the authors.  
6  
7

8 The summary assessment of risk of bias will be considered for each important outcome within  
9 each study (across domains) and across studies presented in summary tables. We will use the  
10 summaries to make judgements about the quality of evidence. We will create additional tables  
11 listing the identified confounders as columns and the studies as rows, indicating the results of  
12 assessments of each confounder for every study. We will also develop a table of comparisons  
13 and outcomes. A comparison of results will be done between results from studies assessed at  
14 high or unclear risk of bias and from those studies at low risk of bias. Comparison will further  
15 be drawn between outcomes for the various study designs, durations of delivery for each study,  
16 frequency of intervention delivery reported, and priority health promotion action area that each  
17 WHP program focuses on. The six health promotion priority areas outlined in the Ottawa  
18 Charter [9] will be applied.  
19  
20  
21  
22  
23  
24  
25  
26

27 Assessment for sustainability will be adopted from the conceptual frameworks developed by  
28 Shediac-Rizkallah and Bone [47] and adopted by Cochrane handbook for systematic reviews  
29 in public health and health promotion. The operational indicators that will be assessed will be  
30 categorised as follows; maintenance of health benefits achieved through an initial program,  
31 level of institutionalisation of a program within an organisation and measures of capacity  
32 building in the workplace setting. To evaluate specific conditions or strategies that favour  
33 sustainability in the LMICs context, a criterion assessing three groups of factors will be applied;  
34 project design and implementation factors, factors within the organisational setting and factors  
35 in the broader community environment such as cultural factors [47].  
36  
37  
38  
39  
40  
41  
42

43 Additionally, the reviewers will carry out a thematic analysis to present and discuss the main  
44 themes across different workplace types, time periods and geographical distribution of included  
45 studies. In addition to the manual data entry and summary, we will complement this analysis  
46 with the use of Leximancer Version 4 software.  
47  
48  
49

### 50 **Patient and Public Involvement**

51 We will not involve patients and the public in this review.  
52  
53  
54

### 55 **Reporting this review**

56 We will report the systematic review according to the checklist of items to include when  
57 reporting a systematic review as per the PRISMA 2009 statement [48]. We will present a flow  
58  
59  
60

1  
2  
3 diagram to show the study selection process, specifying reasons for exclusion at each stage.  
4  
5 The study quality appraisal tool will be availed as online supplementary material.  
6

### 7 **Potential amendments**

8 In case of any changes to this protocol, we will outline the details of the changes in the final  
9 report. However, no further amendments to this protocol are foreseen.  
10

### 11 **Conclusion**

12 To heed to the WHO's clarion call to implement and scale-up effective health promotion  
13 interventions in Africa [3], there is a need to assess what has been effective and sustainable in  
14 the context of the workplace setting. There is need to "...establish what has worked...and what  
15 should be done here and now, to improve the health of the people in Africa" [3] and the rest of  
16 the LMICs.  
17

18 Previous reviews on WHP focused on the effectiveness of specific interventions; for example,  
19 on physical activity [49, 50], nutrition promotion [51] and smoking cessation [28]. Through  
20 this comprehensive review, we will provide new insights by presenting a holistic outline of  
21 current WHP practice in LMICs, with a focus on effectiveness and sustainability.  
22

### 23 **Ethics and dissemination**

24 Since systematic reviews are based on available published data, this review will therefore not  
25 require any formal ethical approval. We will disseminate the results of this systematic review  
26 through peer-reviewed publications and conference presentations.  
27

### 28 **Authors' Contributions**

29 MNW conceived the paper and wrote the first draft. BZD and JLV provided revisions to the  
30 manuscript. All authors read and approved the final manuscript. MNW is the guarantor of the  
31 review.  
32

### 33 **Data sharing Statement**

34 All data for this manuscript are included in the submission.  
35

### 36 **Funding Statement**

37 This research received no specific grant from any funding agency in the public, commercial or  
38 not-for profit sectors.  
39

### 40 **Competing interests Statement**

41 None declared.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. World Health Organisation. *World Health Statistics*. 2018 [26th November 2018]; Available from: <https://apps.who.int/iris/bitstream/handle/10665/272596/9789241565585-eng.pdf?ua=1>.
2. WHO. *Non communicable diseases*. 2019 [20th March 2019]; Available from: <https://www.who.int/en/news-room/fact-sheets/detail/noncommunicable-diseases>.
3. WHO. *The African Regional Health Report: The Health of the People*. 2014; Available from: [www.who.int/bulletin/africanhealth/en](http://www.who.int/bulletin/africanhealth/en).
4. WHO. *Chronic diseases and health promotion: Preventing chronic diseases: a vital investment*. 2005; Available from: [http://www.who.int/chp/chronic\\_disease\\_report/contents/foreword.pdf?ua=1](http://www.who.int/chp/chronic_disease_report/contents/foreword.pdf?ua=1).
5. WHO. *Health Promotion: 7th Global Conference on Health Promotion, Nairobi Call to Action*. 2009a; Available from: <http://www.who.int/healthpromotion/conferences/7gchp/en/>.
6. K.A. Sampson, U., M. Amuyunzu-Nyamongo, and G. Mensah, *Health Promotion and Cardiovascular Disease Prevention in Sub-Saharan Africa*. Vol. 56. 2013. 344-355.
7. WHO. *Global Health Risks*. 2009b; Available from: [www.who.int/healthinfo/global\\_burden\\_disease/GlobalHealthRisks\\_report\\_full.pdf](http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf).
8. WHO. *Noncommunicable diseases and their risk factors. Prevention of noncommunicable diseases 2019* [25th March 2019]; Available from: <https://www.who.int/ncds/prevention/introduction/en/>.
9. WHO. *The Ottawa Charter for Health promotion: an International Conference on Health Promotion, the move towards a new public health*. 1986 [21st November 2019]; Available from: [www.who.int/healthpromotion/conferences/previous/ottawa/en/](http://www.who.int/healthpromotion/conferences/previous/ottawa/en/).
10. WHO. *Health Promotion: Jakarta Declaration on Leading Health Promotion into the 21st Century*. 1997; Available from: <http://www.who.int/healthpromotion/conferences/previous/jakarta/declaration/en/>.
11. Nyamwaya, D., *Health promotion in Africa: strategies, players, challenges and prospects*. Health Promotion International, 2003. **18**(2): p. 85-87.
12. Nutbeam, D., *What would the Ottawa Charter look like if it were written today?* Vol. 18. 2008. 435-441.
13. Kickbusch and Ilona, *Tribute to Aaron Antonovsky—'What creates health'*. Health Promotion International, 1996. **11**(1): p. 5-6.
14. Lankford, et al., *Workplace Health: Engaging Business Leaders to Combat Obesity*. Journal of Law, Medicine & Ethics, 2013. **41**: p. 40-45.
15. Goetzel Ron Z and O.R. J, *The health and cost benefits of work site health-promotion programs*. Annu. Rev. Public Health, 2008. **29**: p. 303-323.
16. WHO. *Workers' health: global plan of action*. 2007; Available from: [http://www.who.int/occupational\\_health/WHO\\_health\\_assembly\\_en\\_web.pdf?ua=1](http://www.who.int/occupational_health/WHO_health_assembly_en_web.pdf?ua=1).
17. Conrad, P., *Health and fitness at work: A participants' perspective*. Social Science & Medicine, 1988. **26**(5): p. 545-550.
18. Harden A, et al., *A systematic review of the effectiveness of health promotion interventions in the workplace*. Occup Med (Lond), 1999. **49**(8): p. 540-8.
19. CDC. *Workplace Health Promotion*. 2019 February 8, 2019 [30th March 2019]; Available from: <https://www.cdc.gov/workplacehealthpromotion/index.html>.
20. Oberlinner, C., et al., *[Prevention of overweight and obesity in the workplace. BASF-health promotion campaign "trim down the pounds--losing weight without losing your mind"]*. Gesundheitswesen, 2007. **69**(7): p. 385-92.
21. Robroek, S.J.W., F.J. van Lenthe, and A. Burdorf, *The role of lifestyle, health, and work in educational inequalities in sick leave and productivity loss at work*. International archives of occupational and environmental health, 2013. **86**(6): p. 619-627.
22. Chalupka, S., *Workplace obesity prevention*. Aaohn j, 2011. **59**(5): p. 236.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
23. Terry, P.E., et al., *The effectiveness of a telephone-based tobacco cessation program offered as part of a worksite health promotion program*. *Popul Health Manag*, 2011. **14**(3): p. 117-25.
24. O'Connell, K.A., V.L. Hosein, and J.E. Schwartz, *Thinking and/or doing as strategies for resisting smoking*. *Research in Nursing & Health*, 2006. **29**(6): p. 533-542.
25. Eves, F.F., et al., *A multi-component stair climbing promotional campaign targeting calorific expenditure for worksites; a quasi-experimental study testing effects on behaviour, attitude and intention*. *BMC Public Health*, 2012. **12**(1): p. 423.
26. Mattke S, et al., *Workplace Wellness Programs Study: Final Report*. *Rand Health Q*, 2013. **3**(2): p. 7.
27. Cancelliere, C., et al., *Are workplace health promotion programs effective at improving presenteeism in workers? A systematic review and best evidence synthesis of the literature*. *BMC public health*, 2011. **11**(1): p. 395.
28. Moher, M., et al., *Workplace interventions for smoking cessation*. *Cochrane Database of Systematic Reviews*, 2005(2).
29. Eng, J.Y., F.M. Moy, and A. Bulgiba, *Impact of a Workplace Health Promotion Program on Employees' Blood Pressure in a Public University*. *PLoS ONE*, 2016. **11**(2): p. e0148307.
30. Edwardson, C.L., et al., *Effectiveness of the stand more at (SMaRT) work intervention: Cluster randomised controlled trial*. *BMJ (Online)*, 2018. **363**.
31. Wilson, M.G., P.B. Holman, and A. Hammock, *A comprehensive review of the effects of worksite health promotion on health-related outcomes*. *Am J Health Promot*, 1996. **10**(6): p. 429-35.
32. Jackson, N. and E. Waters, *Criteria for the systematic review of health promotion and public health interventions*. *Health Promot Int*, 2005. **20**(4): p. 367-74.
33. Linnan, L., et al., *Results of the 2004 National Worksite Health Promotion Survey*. *American Journal of Public Health*, 2008. **98**(8): p. 1503-1509.
34. Swerissen, H. and B.R. Crisp, *The sustainability of health promotion interventions for different levels of social organization*. *Health Promot Int*, 2004. **19**(1): p. 123-30.
35. Robroek, S.J.W., et al., *Determinants of participation in worksite health promotion programmes: a systematic review*. *International Journal of Behavioral Nutrition and Physical Activity*, 2009. **6**(1): p. 26.
36. Lowensteyn, I., et al., *The Sustainability of a Workplace Wellness Program That Incorporates Gamification Principles: Participant Engagement and Health Benefits After 2 Years*. *American Journal of Health Promotion*, 2019: p. 0890117118823165.
37. Malik, S.H., H. Blake, and L.S. Suggs, *A systematic review of workplace health promotion interventions for increasing physical activity*. *British Journal of Health Psychology*, 2014. **19**(1): p. 149-180.
38. Wolfenden, L., et al., *Strategies to improve the implementation of workplace-based policies or practices targeting tobacco, alcohol, diet, physical activity and obesity*. *The Cochrane Database Of Systematic Reviews*, 2018. **11**: p. CD012439.
39. Freak-Poli, R.L.A., et al., *Workplace pedometer interventions for increasing physical activity*. *The Cochrane Database Of Systematic Reviews*, 2013(4): p. CD009209.
40. David Moher, L.S., Mike Clarke, Davina Gherzi, Alessandro Liberati, Mark Petticrew, Paul Shekelle, Lesley A Stewart and PRISMA-P Group *Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement*. 2015.
41. Baum, F., *Researching public health: behind the qualitative-quantitative methodological debate*. *Soc Sci Med*, 1995. **40**(4): p. 459-68.
42. Donner, A. and N. Klar, *Pitfalls of and controversies in cluster randomization trials*. *American Journal of Public Health*, 2004. **94**(3): p. 416-422.
43. Glasziou, P., J. Vandenbroucke, and I. Chalmers, *Assessing the quality of research*. *Bmj*, 2004. **328**(7430): p. 39-41.

- 1  
2  
3 44. Mourad Ouzzani, H.H., Zbys Fedorowicz, and Ahmed Elmagarmid. . *Rayyan — a web and*  
4 *mobile app for systematic reviews*. 2016 [cited 2018 15th September 2018]; 5:210:[DOI:  
5 10.1186/s13643-016-0384-4].  
6  
7 45. Reeves BC, et al., *Including non-randomized studies*. , in *Cochrane Handbook for Systematic*  
8 *Reviews of Interventions*, G.S. Higgins JPT, Editor. 2011, The Cochrane Collaboration.  
9 46. Higgins, A., Sterne JAC *Assessing risk of bias in included studies*. 2011: Cochrane Handbook  
10 for Systematic Reviews of Interventions  
11 47. Shediak-Rizkallah, M.C. and L.R. Bone, *Planning for the sustainability of community-based*  
12 *health programs: conceptual frameworks and future directions for research, practice and*  
13 *policy*. Health Educ Res, 1998. **13**(1): p. 87-108.  
14 48. Moher, D., et al., *Preferred reporting items for systematic reviews and meta-analyses: the*  
15 *PRISMA statement*. PLoS Med, 2009. **6**(7): p. e1000097.  
16 49. Marshall, A.L., *Challenges and opportunities for promoting physical activity in the workplace*.  
17 *Journal of science and medicine in sport / Sports Medicine Australia*, 2004. **7**(1 Suppl): p. 60-  
18 66.  
19 50. Proper, K.I., et al., *The effectiveness of worksite physical activity programs on physical*  
20 *activity, physical fitness, and health*. Clinical Journal of Sport Medicine, 2003. **13**(2): p. 106-  
21 117.  
22 51. Janer, G., M. Sala, and M. Kogevinas, *Health promotion trials at worksites and risk factors for*  
23 *cancer*. Scandinavian Journal of Work, Environment and Health, 2002. **28**(3): p. 141-157.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Quality Appraisal tool from *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011).

Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: Including non-randomized studies. In: Higgins JPT, Green S (editors), *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [www.handbook.cochrane.org](http://www.handbook.cochrane.org).

Developing criteria for including non-randomized studies > Table 13.2.a: List of study design features (studies with allocation to interventions at the

**Table 13.2.a: List of study design features (studies with allocation to interventions at the individual level)**

	RCT	Q-RCT	NRCT	CBA	PCS	RCS	HCT	MC	CC	XS	BA	CR/CS
<i>Was there a comparison:</i>												
Between two or more groups of participants receiving different interventions?	Y	Y	Y	Y	Y	Y	Y		Y	Y	N	N
Within the same group of participants over time?	P	P	N	Y	N	N	N		N	N	Y	N
<i>Were participants allocated to groups by:</i>												
Concealed randomization?	Y	N	N	N	N	N	N		N	N	na	na
Quasi-randomization?	N	Y	N	N	N	N	N		N	N	na	na
By other action of researchers?	N	N	Y	P	N	N	N		N	N	na	na
Time differences?	N	N	N	N	N	N	Y		N	N	na	na
Location differences?	N	N	P	P	P	P	P		na	na	na	na
Treatment decisions?	N	N	N	P	P	P	N		N	P	na	na
Participants' preferences?	N	N	N	P	P	P	N		N	P	na	na
On the basis of outcome?	N	N	N	N	N	N	N		Y	P	na	na
Some other process? (specify)												
<i>Which parts of the study were prospective:</i>												
Identification of participants?	Y	Y	Y	P	Y	N	P*		N	N	P	P
Assessment of baseline and allocation to intervention?	Y	Y	Y	P	Y	N	P*		N	N	na	na
Assessment of outcomes?	Y	Y	Y	P	Y	P	P		N	N	P	P



Generation of hypotheses?	Y	Y	Y	Y	Y	Y	Y	Y	P	P	P	na
<i>On what variables was comparability between groups assessed:</i>												
Potential confounders?	P	P	P	P	P	P	P	P	P	P	N	na
Baseline assessment of outcome variables?	P	P	P	Y	P	P	P	P	N	N	N	na

Y=Yes; P=Possibly; P\*=Possible for one group only; N=No; na=not applicable. NB.: Note that 'possibly' is used in the table to indicate cells where either 'Y' or 'N' may be the case. It should not be used as a response option when applying the checklist; if uncertain, the response should be 'can't tell' (see [Box 13.4.a](#)).

RCT=Randomized controlled trial; Q-RCT=Quasi-randomized controlled trial; NRCT=Non-randomized controlled trial; CBA=Controlled before-and-after study; PCS=Prospective cohort study; RCS=Retrospective cohort study; HCT=Historically controlled trial; NCC=Nested case-control study; CC=Case-control study; XS=Cross-sectional study; BA=Before-and-after comparison; CR/CS=Case report/Case series

Table 13.2.b: List of study design features (studies with allocation to interventions at the group

**Table 13.2.b: List of study design features (studies with allocation to interventions at the group level)**

	CIRCT	CIQ-RCT	CINRT	CITS	CChBA	ITS	ChBA	EcoXS
<i>Was there a comparison:</i>								
Between two or more groups of clusters receiving different interventions?	Y	Y	Y	Y	Y	N	N	Y
Within the same group of clusters over time?	P	P	N	Y	N	Y	Y	N
<i>Were clusters allocated to groups by:</i>								
Concealed randomization?	Y	N	N	N	N	N	N	N
Quasi-randomization?	N	Y	N	N	N	N	N	N
By other action of researchers?	N	N	Y	P	P	N	N	N
Time differences?	N	N	N	Y	Y	Y	Y	N
Location differences?	N	N	P	P	P	N	N	P
Policy/public health decisions?	Na	na	P	P	P	P	na	na
Cluster preferences?	Na	na	P	P	P	P	na	na
Some other process? (specify)								
<i>Which parts of the study were prospective:</i>								
Identification of participating clusters?	Y	Y	Y	P	P	P	P	N
Assessment of baseline and allocation to intervention?	Y	Y	Y	P	P	P	P	N

Assessment of outcomes?	Y	Y	Y	P	P	P	P	N
Generation of hypotheses?	Y	Y	Y	Y	Y	Y	Y	P
<i>On what variables was comparability between groups assessed:</i>								
Potential confounders?	P	P	P	P	P	P	P	P
Baseline assessment of outcome variables?	P	P	P	Y	Y	Y	Y	N

Note that 'cluster' refers to an entity (e.g. an organization), not necessarily to a group of participants; 'group' refers to one or more clusters; see [Box 13.4.a](#).

Note that 'possibly' is used in the table to indicate cells where *either* 'Y' or 'N' may be the case. It should not be used as a response option when applying the checklist; if uncertain, 'can't tell' should be used (see [Box 13.4.a](#)).

Y=Yes; P=Possibly; P\*=Possible for one group only; N=No; NR=Not required. CIRCT=Cluster randomized controlled trial; CIQ-RCT=Cluster quasi-randomized controlled trial; CINRT=Cluster non-randomized controlled trial; CITS=Controlled interrupted time series (Shadish 2002); CChBA=Controlled cohort before-and-after study (Shadish 2002); ITS=Interrupted time series; ChBA=Cohort before and after study (Shadish 2002); EcoXS=Ecological cross-sectional study.

**Box 13.4.a: User guide for data collection/study assessment using checklist in [Table 13.2.a](#) or [Table 13.2.b](#)**

Note: Users need to be very clear about the way in which the terms 'group' and 'cluster' are used in these tables. [Table 13.2.a](#) only refers to groups, which is used in its conventional sense to mean a number of individual participants. With the exception of allocation on the basis of outcome, 'group' can be interpreted synonymously with 'intervention group'. [Table 13.2.b](#) refers to both clusters and groups. In this table, 'clusters' are typically an organizational entity such as a family health practice, or administrative area, not an individual. As in [Table 13.2.a](#), 'group' is synonymous with 'intervention group' and is used to describe a collection of allocated units, but in [Table 13.2.b](#) these units are clusters rather than individuals. Furthermore, although individuals are nested in clusters, a cluster does not necessarily represent a fixed collection of individuals. For instance, in cluster-allocated studies, clusters are often studied at two or more time-points (periods) with different collections of individuals contributing to the data collected at each time-point.

*Was there a comparison?*

Typically, researchers compare two or more groups that receive different interventions; the groups may be studied over the same time period, or over different time periods (see below). Sometimes researchers compare outcomes in just one group but at two time-points. It is also possible that researchers may have done both, i.e. studying two or more groups and measuring outcomes at more than one time-point.

*Were participants/clusters allocated to groups by?*

These items aim to describe how groups were formed. None will apply if the study does not compare two or more groups of subjects. The information is often not reported or is difficult to find in a paper. The items provided cover the main ways in which groups may be formed. More than one option may apply to a single study, although some options are mutually exclusive (i.e. a study is either randomized or not).

6/bmjopen-2018-027050 on 22 May 2019. Downloaded from <http://bmjopen.bmj.com/>. Protected by copyright.

1  
2  
3  
4 Randomization: Allocation was carried out on the basis of truly random sequence. Such studies are covered by the standard guidance  
elsewhere in this *Handbook*. Check carefully whether allocation was adequately concealed until subjects were definitively recruited.  
5  
6 Quasi-randomization: Allocation was done on the basis of a pseudo-random sequence, e.g. odd/even hospital number or date of birth,  
7 alternation. Note: when such methods are used, the problem is that allocation is rarely concealed. These studies are often included in  
8 systematic reviews that only include randomized trials, using assessment of the risk of bias to distinguish them from properly randomized  
9 trials.

10 By other action of researchers: This is a catch-all category and further details should be noted if the researchers report them. Allocation  
11 happened as the result of some decision or system applied by the researchers. For example, subjects managed in particular 'units' of  
12 provision (e.g. wards, general practices) were 'chosen' to receive the intervention and subjects managed in other units to receive the control  
13 intervention.

14 Time differences: Recruitment to groups did not occur contemporaneously. For example, in a historically controlled study subjects in the control  
15 group are typically recruited earlier in time than subjects in the intervention group; the intervention is then introduced and subjects receiving  
16 the intervention are recruited. Both groups are usually recruited in the same setting. If the design was under the control of the researchers,  
17 both this option and 'other action of researchers' must be ticked for a single study. If the design 'came about' by the introduction of a new  
18 intervention, both this option and 'treatment decisions' must be ticked for a single study.

19 Location differences: Two or more groups in different geographic areas were compared, and the choice of which area(s) received the  
20 intervention and control interventions was not made randomly. So, both this option and 'other action of researchers' could be ticked for a  
21 single study.

22 Treatment decisions: Intervention and control groups were formed by naturally occurring variation in treatment decisions. This option is  
23 intended to reflect treatment decisions taken mainly by the clinicians responsible; the following option is intended to reflect treatment  
24 decisions made mainly on the basis of subjects' preferences. If treatment preferences are uniform for particular provider 'units', or switch  
25 over time, both this option and 'location' or 'time' differences should be ticked.

26 Patient preferences: Intervention and control groups were formed by naturally occurring variation in patients' preferences. This option is  
27 intended to reflect treatment decisions made mainly on the basis of subjects' preferences; the previous option is intended to reflect treatment  
28 decisions taken mainly by the clinicians responsible.

29 On the basis of outcome: A group of people who experienced a particular outcome of interest were compared with a group of people who did  
30 not, i.e. a case-control study. Note: this option should be ticked for papers that report analyses of *multiple risk factors for a particular*  
31 *outcome* in a large series of subjects, i.e. in which the total study population is divided into those who experienced the outcome and those  
32 who did not. These studies are much closer to nested case-control studies than cohort studies, even when longitudinal data are collected  
33 prospectively for consecutive patients.

34  
35 Additional options for cluster-allocated studies.  
36 Location differences: see above.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

1  
2  
3 Policy/public health decisions: Intervention and control groups were formed by decisions made by people with the responsibility for  
4 implementing policies about public health or service provision. Where such decisions are coincident with clusters, or where such people are  
5 the researchers themselves, this item overlaps with 'other action of researchers' and 'cluster preferences'.

6 Cluster preferences: Intervention and control groups were formed by naturally occurring variation in the preferences of clusters, e.g.  
7 preferences made collectively or individually at the level of the cluster entity.

8  
9 *Which parts of the study were prospective?*

10 These items aim to describe which parts of the study were conducted prospectively. In a randomized controlled trial, all four of these items  
11 would be prospective. For NRS it is also possible that all four are prospective, although inadequate detail may be presented to discern this,  
12 particularly for generation of hypotheses. In some cohort studies, participants may be identified, and have been allocated to treatment  
13 retrospectively, but outcomes are ascertained prospectively.

14 *On what variables was comparability of groups assessed?*

15 These questions should identify 'before-and-after' studies. Baseline assessment of outcome variables is particularly useful when outcomes are  
16 measured on continuous scales, e.g. healthstatus or quality of life.

17 *Response options*

18 Try to use only 'Yes', 'No' and 'Can't tell' response options. 'N/a' should be used if a study does not report a comparison between groups.  
19  
20  
21

22 Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: Including non-randomized studies. In: Higgins JPT, Green S (editors), *Cochrane Handbook for*  
23 *Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [www.handbook.cochrane.org](http://www.handbook.cochrane.org).  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

# Reporting checklist for protocol of a systematic review.

Based on the PRISMA-P guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-P reporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. *Syst Rev.* 2015;4(1):1.

		Reporting Item	Page Number
Identification	<a href="#">#1a</a>	Identify the report as a protocol of a systematic review	1
Update	<a href="#">#1b</a>	If the protocol is for an update of a previous systematic review, identify as such	n/a not an update
	<a href="#">#2</a>	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Contact	<a href="#">#3a</a>	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	<a href="#">#3b</a>	Describe contributions of protocol authors and identify the guarantor of the review	10
	<a href="#">#4</a>	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	n/a not an amendment

1	Sources	<a href="#">#5a</a>	Indicate sources of financial or other support for the review	10
2				
3				
4	Sponsor	<a href="#">#5b</a>	Provide name for the review funder and / or sponsor	10
5				
6				
7	Role of sponsor or funder	<a href="#">#5c</a>	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	n/a- has no funder
8				
9				
10				
11	Rationale	<a href="#">#6</a>	Describe the rationale for the review in the context of what is already known	3-5
12				
13				
14	Objectives	<a href="#">#7</a>	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	5
15				
16				
17				
18				
19				
20	Eligibility criteria	<a href="#">#8</a>	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6
21				
22				
23				
24				
25				
26				
27	Information sources	<a href="#">#9</a>	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	6
28				
29				
30				
31				
32				
33				
34	Search strategy	<a href="#">#10</a>	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	6-7
35				
36				
37				
38				
39	Study records - data management	<a href="#">#11a</a>	Describe the mechanism(s) that will be used to manage records and data throughout the review	7
40				
41				
42				
43	Study records - selection process	<a href="#">#11b</a>	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	7
44				
45				
46				
47				
48				
49	Study records - data collection process	<a href="#">#11c</a>	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	7
50				
51				
52				
53				
54				
55				
56	Data items	<a href="#">#12</a>	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned	7- 8
57				
58				
59				
60				

data assumptions and simplifications

1			
2			
3	Outcomes and	<a href="#">#13</a>	List and define all outcomes for which data will be sought, 5,9
4	prioritization		including prioritization of main and additional outcomes,
5			with rationale
6			
7			
8	Risk of bias in	<a href="#">#14</a>	Describe anticipated methods for assessing risk of bias of 8-9
9	individual studies		individual studies, including whether this will be done at
10			the outcome or study level, or both; state how this
11			information will be used in data synthesis
12			
13			
14	Data synthesis	<a href="#">#15a</a>	Describe criteria under which study data will be 9
15			quantitatively synthesised
16			
17			
18		<a href="#">#15b</a>	If data are appropriate for quantitative synthesis, describe n/a
19			planned summary measures, methods of handling data
20			and methods of combining data from studies, including
21			any planned exploration of consistency (such as I <sup>2</sup> ,
22			Kendall's $\tau$ )
23			
24			
25			
26			
27		<a href="#">#15c</a>	Describe any proposed additional analyses (such as 9
28			sensitivity or subgroup analyses, meta-regression)
29			
30			
31		<a href="#">#15d</a>	If quantitative synthesis is not appropriate, describe the 9
32			type of summary planned
33			
34	Meta-bias(es)	<a href="#">#16</a>	Specify any planned assessment of meta-bias(es) (such 8-9
35			as publication bias across studies, selective reporting
36			within studies)
37			
38			
39			
40	Confidence in	<a href="#">#17</a>	Describe how the strength of the body of evidence will be 8-9
41	cumulative		assessed (such as GRADE)
42	evidence		
43			
44			

The PRISMA-P checklist is distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)